Acute and chronic metabolic responses of transition dairy cows with fatty liver disease to subcutaneous glucagon injections, oral glycerol, or both by Osman, Mohamed Abdulraheem
Retrospective Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2007
Acute and chronic metabolic responses of
transition dairy cows with fatty liver disease to
subcutaneous glucagon injections, oral glycerol, or
both
Mohamed Abdulraheem Osman
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/rtd
Part of the Agriculture Commons, Animal Sciences Commons, Physiology Commons, and the
Veterinary Physiology Commons
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital
Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital
Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Osman, Mohamed Abdulraheem, "Acute and chronic metabolic responses of transition dairy cows with fatty liver disease to
subcutaneous glucagon injections, oral glycerol, or both" (2007). Retrospective Theses and Dissertations. 14896.
https://lib.dr.iastate.edu/rtd/14896
Acute and chronic metabolic responses of transition dairy cows with fatty liver disease  
 
to subcutaneous glucagon injections, oral glycerol, or both 
 
by 
 
Mohamed Abdulraheem Osman 
 
A thesis submitted to the graduate faculty 
 
in partial fulfillment of the requirements for the degree of 
 
MASTER OF SCIENCE 
 
Major:  Nutritional Sciences 
 
Program of Study Committee: 
Donald C. Beitz, Major Professor 
Ronald L. Horst 
Jesse P. Goff 
Diane M. Spurlock 
 
Iowa State University 
 
Ames, Iowa 
 
2007 
 
Copyright © Mohamed Abdulraheem Osman, 2007.  All right reserved. 
UMI Number: 1449654
1449654
2008
UMI Microform
Copyright
All rights reserved. This microform edition is protected against 
    unauthorized copying under Title 17, United States Code.
ProQuest Information and Learning Company 
300 North Zeeb Road
P.O. Box 1346
     Ann Arbor, MI 48106-1346 
 by ProQuest Information and Learning Company. 
ii
TABLE OF CONTENTS 
LIST OF FIGURES ................................................................................................................ iv 
 
LIST OF TABLES.................................................................................................................. vi 
 
CHAPTER 1. GENERAL INTRODUCTION ........................................................................ 1 
 Thesis Organization ........................................................................................................... 1 
 Literature Review............................................................................................................... 1 
 Introduction.................................................................................................................. 1 
 Etiology of Fatty Liver Disease ................................................................................... 3 
 Fatty Liver-Related Health Disorders........................................................................ 10 
 Role of Glycerol in Glucose and NEFA Homeostasis............................................... 15 
 Role of Glucagon in Glucose Homeostasis ............................................................... 17 
 Gluconeogenesis ........................................................................................................ 25 
 Prevention and Treatment of Fatty Liver Disease and Fatty Liver-Related  
 Health Disorders .................................................................................................. 28 
 
CHAPTER 2. ACUTE METABOLIC RESPONSES OF TRANSITION DAIRY  
COWS WITH FATTY LIVER DISEASE TO SUBCUTANEOUS GLUCAGON 
INJECTIONS, ORAL GLYCEROL, OR BOTH .................................................................. 33 
 Abstract ............................................................................................................................ 33 
 Introduction...................................................................................................................... 34 
 Material and Methods ...................................................................................................... 36 
 Experimental Design.................................................................................................. 36 
 Sampling and Analysis .............................................................................................. 38 
 Statistical Analysis..................................................................................................... 39 
 Results.............................................................................................................................. 40 
 Plasma Constituents ................................................................................................... 40 
 Discussion ........................................................................................................................ 51 
 Conclusion ....................................................................................................................... 57 
 Acknowledgements.......................................................................................................... 56 
 References........................................................................................................................ 58 
 
CHAPTER 3. CHRONIC METABOLIC RESPONSES OF TRANSITION  
DAIRY COWS WITH FATTY LIVER DISEASE TO SUBCUTANEOUS  
GLUCAGON INJECTIONS, ORAL GLYCEROL, OR BOTH........................................... 65 
 Abstract ............................................................................................................................ 65 
 Introduction...................................................................................................................... 66 
 Material and Methods ...................................................................................................... 68 
 Experimental Design.................................................................................................. 68 
 Sampling and Analysis .............................................................................................. 69 
 Statistical Analysis..................................................................................................... 70 
 Results.............................................................................................................................. 72 
 Plasma Constituents ................................................................................................... 72 
iii
Liver Composition ..................................................................................................... 76 
 Discussion ........................................................................................................................ 81 
 Conclusion ....................................................................................................................... 88 
 Acknowledgments............................................................................................................ 89 
 References........................................................................................................................ 89 
 
CHAPTER 4. GENERAL CONCLUSIONS......................................................................... 95 
 General Discussion .......................................................................................................... 95 
 Recommendations for Future Research ........................................................................... 97 
 
REFERENCES .................................................................................................................... 100 
 
ACKNOWLEDGMENTS ................................................................................................... 114 
 
iv
LIST OF FIGURES 
 
CHAPTER 1  
 
Figure 1. Pathogenesis of fatty liver and fatty liver-related peripartal health disorders.......... 5 
 
Figure 2. Metabolic use of glycerol ....................................................................................... 16 
 
Figure 3. Proteolytic processing of proglucagon in the B-cells of the pancreas and  
L-cells of the duodenum ......................................................................................... 18 
 
Figure 4. Glucagon signaling pathway .................................................................................. 20 
 
Figure 5. Mechanisms by which glucagon regulates gluconeogenesis and glycolysis.......... 23 
 
CHAPTER 2 
 
Figure 1. Plasma glucagon concentrations of cows treated with saline, glucagon,  
glycerol, or glucagon plus glycerol on d 1, d 7, and d 13 postpartum ................... 41 
 
Figure 2. Plasma glucose of cows treated with saline, glucagon, glycerol,  
or glucagon plus glycerol on d 1, d 7, and d 13 postpartum................................... 43 
 
Figure 3. Plasma insulin concentrations of cows treated with saline, glucagon, glycerol,  
or glucagon plus glycerol on d 1, d 7, and d 13 postpartum................................... 44 
 
Figure 4. Plasma NEFA concentrations of cows treated with saline, glucagon,  
glycerol, or glucagon plus glycerol on d 1, d 7, and d 13 postpartum ................... 46 
 
Figure 5. Plasma BHBA concentrations of cows treated with saline, glucagon,  
glycerol, or glucagon plus glycerol on d 1, d 7, and d 13 postpartum ................... 47 
 
Figure 6. Plasma TAG concentrations of cows treated with saline, glucagon, glycerol,  
or glucagon plus glycerol on d 1, d 7, and d 13 postpartum................................... 49 
 
Figure 7. Plasma urea N concentrations of cows treated with saline, glucagon, glycerol,  
or glucagon plus glycerol on d 1, d 7, and d 13 postpartum................................... 50 
 
CHAPTER 3 
 
Figure 1. Plasma hormone concentrations of cows treated with saline, glucagon,  
glycerol, or glucagon plus glycerol ........................................................................ 73 
 
Figure 2. Plasma metabolite concentrations of cows treated with saline, glucagon,  
glycerol, or glucagon plus glycerol ........................................................................ 75 
vFigure 3. Body condition scores of cows treated with saline, glucagon, glycerol, or 
 glucagon plus glycerol........................................................................................... 77 
 
Figure 4. Milk  production of cows treated with saline, glucagon, glycerol, or  
glucagon plus glycerol............................................................................................ 78 
 
Figure 5. Liver composition on d 9 postpartum of cows treated with saline, glucagon, 
glycerol, or glucagon plus glycerol ........................................................................ 79 
 
vi
LIST OF TABLES 
CHAPTER 3 
 
Table 1. Incidence of fatty liver-related peripartal health disorders of cows treated with 
saline, glucagon, glycerol, or glucagon plus glycerol during the first 14 days  
of the postpartal period............................................................................................ 77 
 
1CHAPTER 1.  GENERAL INTRODUCTION 
Thesis Organization 
This thesis is presented as two complete papers with abstracts, introductions, materials 
and methods, results, discussions, conclusions, acknowledgements, and references for 
submission to the Journal of Dairy Science. The title of the first paper is “Acute Metabolic 
Responses of Postpartal Dairy Cows to Subcutaneous Glucagon Injections, Oral Glycerol, or 
Both”.  The title of the second paper is “Chronic Metabolic Responses of Postpartal Dairy 
Cows to Subcutaneous Glucagon Injections, Oral Glycerol, or Both.” The thesis was 
prepared from research conducted to partly fulfill the requirements for a Master of Science 
degree. The data indicate that glycerol, glucagon, and glucagon plus glycerol are potential 
treatments for energy status-related health disorders. The combination treatment is superior 
to glucagon injections or oral glycerol alone in rapid alleviation of energy status-related 
health disorders because glucagon and glycerol biochemical actions are additive. The papers 
are preceded by a literature review and are followed by a general discussion and 
recommendations for future research. The list of references concludes the thesis. 
Literature Review 
Introduction 
Fatty liver (i.e., nonalcoholic steatohepatitis or hepatic lipidosis) is a major metabolic 
disease that affects animals (Grummer, 1993; Katoh, 2002) and humans (Farrell and Larter, 
2006).  In dairy cows, fatty liver occurs during the transition period (from 3 wk prepartum to 
3 wk postpartum) mostly during the first 4 weeks of lactation (Grummer, 1993; Drackley, 
1999). Approximately 50 % of multiparous dairy cows experience moderate to severe fatty 
2liver disease postpartum (Bremmer et al., 2000). Fatty liver is associated with increased 
incidence of metabolic and infectious health disorders and decreased productive and 
reproductive efficiency (Bobe et al., 2004).  
The primary risk factor for fatty liver disease is over-conditioning of dairy cows during 
the dry period (Katoh, 2002). During the peripartal period, dry matter intake (DMI) decreases 
about 30 % (Bertics et al., 1992; Doepel et al., 2002; Hayirli et al., 2002) and because of the 
progressive increase of energy and nutrients demand by the growing size of the gravid uterus 
prepartum and by the mammary gland to initiate lactogenesis postpartum, the dairy cow 
develops severe negative energy balance (NEB) that reaches -16 Mcal/d (Doepel et al., 2002; 
Goff and Horst, 1997).  
The NEB is compensated for by mobilization of nonesterified fatty acids (NEFA) from 
adipose tissues (Katoh, 2001). NEFA are exported from adipose tissues bound to serum 
albumin and mainly taken-up by the liver. In liver, NEFA undergo J-oxidation in 
mitochondria and peroxisomes to supply energy for the hepatic tissue. Excess NEFA are 
esterified to a glycerol backbone and form triacylglycerols (TAG). Newly synthesized TAG 
are either exported as a very low-density lipoprotein (VLDL) or stored in the liver when 
VLDL is limiting.  
Fatty liver disease develops in different degrees when uptake of NEFA by the liver far 
exceeds their oxidation or secretion as TAG-VLDL (Bremmer, 2000; Katoh, 2002; Donnelly 
et al., 2004). Although rate of hepatic TAG synthesis in ruminants is similar to that of 
nonruminants, ruminants have extremely slow secretion of VLDL (Pullen et al., 1990).  
Fatty liver impairs the functions of the immune system peripartum, making the dairy cow 
especially vulnerable to develop mastitis (Zerbe et al., 2000), retained fetal membranes, and 
3endometritis (LeBlanc et al., 2004; Kimura et al., 2002). The dairy cow with fatty liver is at a 
high risk to develop left displacement of the abomasum postpartum (Holtenius and Traven, 
1990; Oikawa et al., 1997) and impairment of reproductive performance (Jorritsma et al., 
2003; Rukkwamsuk et al., 1999). Furthermore, fatty liver slows gluconeogenesis from 
propionate, causing disturbance of the energy metabolism and glucose homeostasis and thus 
predisposing the dairy cow to develop postpartal ketosis (Cadorniga-Valino et al, 1997).  
Etiology of Fatty Liver Disease 
Dairy cows are fed high-energy diets to meet the energy demand for high production. 
Feeding high-energy diets usually continues through late lactation when milk yield decreases, 
allowing for dairy cows to gain body weight and possibly become obese (Katoh, 2002).  
Regardless of the energy density and protein content of the peripartal diets, DMI 
decreases by about 30 % during the 3 weeks before parturition and about 90 % of that DMI 
decrease happens during the last prepartal week (Doepel et al., 2002; Bertics et al., 1992; 
Hayirli et al., 2002). Several factors may be causing the peripartal DMI decrease. First, the 
increasing size of the gravid uterus might physically limit the rumen size, causing decreased 
DMI. Second, because the diet fed during the dry period is usually high in roughage, the 
rumen is not adapted to the high carbohydrate diets fed peripartum and consequently 
indigestion or ruminal acidosis may result that could limit DMI. Third, the endogenous 
opoids (J-endorphins and enkephalins) that are secreted by the pituitary gland and the 
hypothalamus to soothe the parturition discomfort may further exacerbate the decrease of 
DMI by decreasing the gut motility (Grummer, 1993: Goff and Horst, 1997). 
As a consequence of the sharp peripartal decrease in DMI coupled with the progressive 
energy and nutrient demand by the growing fetus, fetal membranes, and the uterus as well as 
4by the mammary gland to initiate lactogensis, the transition dairy cow develops severe NEB 
(Goff and Horst, 1997; Jorritsma et al., 2003) that may reach -16 Mcal/d (Doepel et al., 2002) 
(Figure 1).  
The NEB is compensated for by mobilization of NEFA from the adipose tissues to 
support milk fat production and fuel other metabolic processes (Grummer, 1993; Katoh, 
2002). The appetite of obese cows is depressed significantly on the day of parturition 
compared with that of non-obese cows (Bines et al., 1983). Therefore, obese cows experience 
a greater NEB and increased plasma NEFA concentration. Because the lipolysis in adipose 
tissues of the prepartal, overfed cows are less inhibited by plasma glucose or 3-
hydroxybutyrate, overfed cows experience higher lipolytic rates, higher plasma NEFA 
concentrations, and greater accumulation of hepatic TAG (Rukkwamsuk et al., 1998). 
Therefore, high peripartal plasma NEFA are considered an important risk factor for 
development of postpartal fatty liver disease.  
Mobilized NEFA could be utilized by the mammary gland to make up to 40 % of the 
milk fat in the first few days postpartum (Bell, 1995). To spare glucose for milk lactose 
production, skeletal muscles use some NEFA as an energy source (Overton and Waldron, 
2004). However, significant amount of NEFA are taken up by the liver in proportion to their 
supply to the liver (Reynolds et al., 2003). 
NEFA taken up by the liver are J-oxidized by mitochondria to acetyl-coenzyme A 
(acetyl-CoA) with concomitant release of energy in the form of adenosine triphosphate 
(ATP). Acetyl-CoA is metabolized further with oxaloacetate (OAA) in the tricarboxylic acid 
(TCA) cycle to produce more ATP and carbon dioxide (CO2). Although the ability of the 
liver to oxidize NEFA seem to be similar in both ruminants and nonruminants (Kleppe et al., 
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Figure 1. Pathogenesis of fatty liver and fatty liver-related peripartal health disorders. 
DMI, dry matter intake; NEB, negative energy balance; NEFA, nonesterified fatty 
acids; RP, retained placenta. Adapted from Goff, 2006. 
61988), livers of obese cows oxidize NEFA less efficiently compared with livers of non-obese 
cows (Jesse et al., 1986). Earlier, impaired J-oxidation of NEFA in cows with fatty liver was 
thought to be caused by the decreased activity of carnitine palmitoyl transferase1 (CAT1) 
that translocates NEFA into the mitochondria for oxidation (Mizutani et al., 1999). However, 
in a recent study, Dann and Drackley (2005) reported that neither primary ketosis nor the 
periparturient health disorders significantly affected CAT I activity or sensitivity to inhibition 
by malonyl-CoA. Because ketosis usually is preceded by fatty liver, it could be speculated 
that alterations of CAT I activity has no active role in the etiology of fatty liver pathogenesis 
as well as in the other fatty liver-related peripartal health disorders.  
NEFA may undergo J-oxidation in the peroxisomes as well. Unlike mitochondria 
oxidation, the initial oxidative step in the peroxisomes involves the use of acyl-CoA oxidase 
with concomitant production of hydrogen peroxide and other reactive oxygen species (ROS) 
rather than the reduced nicotinamide dinucleotide (NADH) (Drackley, 1999). As a result, 
less reductive energy is retained as the NADH and more heat is liberated. Furthermore, 
because peroxisomes are not linked directly to the respiratory chain, they do not undertake a 
significant role in the cellular energy metabolism; rather, they primarily function to shorten 
the long-chain fatty acids (LCFA) and to oxidize xenobiotic compounds (Mannaerts and 
Veldhoven, 1993; Yamada et al., 1987).  
Alternative to J-oxidation, NEFA may be converted to TAG and exported to the 
extrahepatic tissues as VLDL or, when VLDL secretion is limiting, stored as TAG in the 
cytosol of the hepatocytes. As previously mentioned, ruminants have inherently slow VLDL 
secretion (Mazur et al., 1989). Research addressing the VLDL assembly and secretion in 
ruminants has elucidated many reasons why VLDL secretion and assembly might be 
7impaired in dairy cows. One reason could be that, because the primary site for NEFA 
synthesis in ruminants is the adipose tissue and not the liver as in nonruminants, ruminants 
have much lower ability to secrete VLDL compared with nonruminants (Pullen et al., 1990).  
More importantly, ApoB-100 is essential for VLDL synthesis and assembly. In cows with 
fatty liver, mRNA abundance of apoB-100 is significantly lower than that of normal cows 
(Mazur et al., 1992). In addition, feed restriction decreased apoB-100 and apoA-I 
concentrations in plasma of Holstein calves and increased plasma NEFA (Katoh et al., 2002). 
Furthermore, Bernabucci et al (2004) observed that postpartal ApoB-100 mRNA abundance 
was correlated negatively with plasma NEFA concentration and correlated positively with 
plasma cholesterol concentration. Consequently, they suggested that ApoB-100 synthesis is 
regulated transcriptionally rather than posttranscriptionally as earlier reported by Gruffat et al 
(1997).  
Decreased DMI during the peripartal period has been thought to limit the essential 
nutrients required for VLDL assembly. However, supplementing the diet with the essential 
nutrients (e.g., methionine and choline) for VLDL assembly did not decrease hepatic TAG 
accumulation (Janovick-Guretzky et al., 2006: Piepenbrink and Overton, 2004).  
Because hepatic TAG microsomal transfer protein (MTP) translocates TAG, cholesteryl 
esters, and phosphatidylcholine into the lumen of endoplasmic reticulum (ER) and 
coordinates the assembly of the VLDL (Wetterau et al., 1997), it was hypothesized that the 
energy content of the diet fed peripartally might alter the function of MTP and consequently 
affects the synthesis of VLDL. Studies on nonlactating dairy cows, however, revealed no 
effect of the energy content of the diet fed prepartum on MTP activity or concentration. 
Furthermore, because MTP concentration, activity, or mRNA abundance did not correlate 
8with liver TAG or plasma NEFA concentration, it was suggested that MTP does not 
contribute to the etiology of fatty liver disease (Bremmer et al., 2000a: 2000b). 
When the amount of NEFA taken up by the liver is in excess of the amount of NEFA that 
is J-oxidized or secreted as TAG-VLDL, TAG accumulate in the liver and fatty liver 
develops (Emery et al., 1992; Bremmer et al., 2000). Moreover, the concurrent postpartal 
increase in the activity of the diacylglycerol acyltransferase enhances hepatic TAG synthesis 
and accumulation (Van den Top et al., 1995). Accumulated hepatic TAG impair the ability of 
hepatocytes to undertake gluconeogenesis efficiently. Incubation of hepatocytes with lipid 
decreased gluconeogenesis from propionate by 24 %, increased the production of ketone 
bodies by 46 % (Cadorniga-Valino et al., 1996), and decreased insulin clearance and 
hormonal control of protein synthesis (Strang et al., 1998). Similarly, activity of phosphoenol 
pyruvate carboxykinase (PEPCK) and fructose-1, 6-bisphosphatase (F-1, 6-BPase) was 
decreased in livers of dairy cows that were overfed during the dry period (Rukkwamsuk et 
al., 1998b).      
Generally, fatty liver disease is defined as the hepatic TAG that exceed 30 mg TAG/g 
liver tissue on wet weight basis (Uchida et al., 1992). More precisely, Bobe et al (2004) 
classified the fatty liver based on the percentage of liver TAG (wet weight basis) into 1) 
normal liver (< 1 % liver TAG), 2) mild fatty liver (1 to 5 % liver TAG), 3) moderate fatty 
liver (5 to 10 % liver TAG), and 4) severe fatty liver (> 10 % liver TAG). 
Histopathological studies have indicated that TAG deposition in the liver is mostly 
defused macrocytic infiltration with frequent occurrence of lipid granulomas. Additionally, 
affected hepatocytes exhibit signs of profound cell injury such as ballooning degeneration, 
Mallory’s bodies formation, and fibrosis (Gramlich et al., 2004). 
9Some physiological factors were thought to enhance hepatic TAG deposition during the 
peripartal period. For instance, elevated concentrations of plasma estrogen, required to 
induce parturition, and glucocorticiodes were implicated with aggravating TAG deposition in 
the liver when plasma NEFA concentration is high (Grummer et al., 1990; Goff and Horst, 
1997). More recent research, however, demonstrated no effect of the prepartal physiological 
rise of estradiol on NEFA metabolism in dairy cows (Bremmer et al., 1999).  
Genetic aberrations that affect fatty acid oxidation in the mitochondria may exacerbate 
TAG deposition in the hepatic tissue. For example, deficiency of the thioredoxin-interacting 
protein increases de novo synthesis of fatty acids and increases their esterification to 
cholesterol and glycerol, resulting in increased hepatic TAG (Donnelly et al., 2004).  
Improper management and husbandry practices may facilitate development of fatty liver. 
For example, unrestricted prepartal feed intake impaired the mitochondrial enzymes involved 
in NEFA oxidation and TCA cycle and decreased the activities of PEPCK and F-1, 6-BPase 
postpartum. Inadequate activities of these key enzymes may result in exacerbated 
accumulation of hepatic TAG and increased ketogenesis postpartum with great implication to 
development of fatty liver-related health disorders (Murondoti et al., 2004; Rukkwamsuk et 
al., 1999).  
Overall, fatty liver impairs the energy metabolism in the affected dairy cow as evident by 
the established inverse correlation among the increased liver TAG and plasma NEFA and 
energy precursors such as citrate and liver glycogen content as well as concentrations of 
plasma structural lipids. Because decreased liver glycogen content increases the 
susceptibility to fatty liver and fatty liver-related peripartal health disorders (Drackley et al., 
10
1992), the ratio of liver TAG to liver glycogen is considered a better diagnostic marker for 
fatty liver disease (Bobe et al., 2004). 
Fatty Liver-Related Health Disorders 
As stated earlier, fatty liver has been associated with increased incidence of different 
peripartal metabolic and infectious health disorders. Fatty liver is associated with impaired 
immune functions peripartum. Impaired immune functions predispose the dairy cow to 
mastitis, retained placenta, and endometritis. Inadequate DMI associated with fatty liver 
makes the cow vulnerable to left displacement of the abomasum, laminitis, milk fever, 
retarded reproductive performance, and ketosis (Figure 1). 
Ketosis  
As mentioned earlier, fatty liver occurs when rate of TAG synthesis exceeds rate of TAG 
hydrolysis and oxidation plus TAG exported as VLDL. Liver synthesizes TAG in proportion 
to plasma NEFA concentration (Grummer, 1993). Thus, fatty liver is likely during period of 
elevated plasma NEFA concentration (Figure 1).  
Fatty liver impairs gluconeogenesis in hepatocytes, rendering the glucose to become 
insufficient to support milk lactose production or to cover peripheral tissues energy demand 
(Cadorniga-Valino et al., 1997; Rukkwamsuk et al., 1998b). Insufficient plasma glucose 
facilitates accelerated lipolytic rate and increased plasma NEFA. The evidence that fatty liver 
causes ketosis could be that fatty liver usually occurs on d 1 postpartum, whereas ketosis 
occurs later in lactation. In agreement with this, Drackley et al (1992) reported that cows 
with hepatic TAG to glycogen ratio of 2.3 developed fatty liver and ketosis, whereas cows 
with hepatic TAG to glycogen ratio of O 0.5 were resistant to ketosis.  
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For the acetyl-CoA that is produced by oxidation of NEFA to be metabolized further in 
the TCA cycle, it must be condensed with OAA, a rat- limiting intermediate of both TCA 
cycle and the gluconeogenesis pathway. During periods of NEB and in part because of the 
decreased DMI, OAA becomes depleted from the mitochondria thus, limiting further 
oxidation of acetyl-CoA in the TCA cycle and allowing for acetyl-CoA to build up 
(Armentano et al., 1990). 
Build up of acetyl-CoA is directed towards ketogenesis to produce ketone bodies such as 
J-hydroxybutyrate (BHBA), acetoacetic acid, and acetone. Elevated ketone bodies in the 
plasma, urine, and milk are diagnostic for ketosis (Katoh, 2002). Moreover, BHBA of > 1.2 
mmol / L of blood or 0.05 to 0.1 mmol / L of milk are considered diagnostic for subclinical 
ketosis (Geishauser et al., 1998).  Therefore, fatty liver is considered to produce almost all 
cases of ketosis (Oikawa et al., 1997).  
A growing body of evidence indicates that ketosis develops because of the accumulated 
TAG in liver. In dairy cows induced with ketosis by feed restriction and 1, 3 butanediol 
feeding, plasma NEFA concentration increased 3-fold and hepatic TAG increased 
significantly from 2 % to 10 % at 2 weeks before the occurrence of clinical ketosis. These 
changes indicated that fatty liver is the number one risk factor for clinical ketosis 
(Veenhuizen et al., 1991). Similarly, in nonlactating feed-restricted cows, the half-life of 
sodium propionate was increased substantially when cows were injected with sodium-
propionate and less propionate was converted to glucose compared with that in fed cows 
(Bruss et al., 1986). 
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Retained Placenta, Endometritis, and Mastitis 
Fatty liver compromises the immune competence during the peripartal period (Figure 1). 
Although the basic molecular mechanism by which the accumulated hepatic TAG retard the 
immune function is poorly understood, increased hepatic TAG impaired both the humoral 
and cellular responses of affected dairy cows (Wentink et al., 1997) and decreased the 
cytotoxic functions  of the polymorph neutrophils (PMN) in their blood and uteri (Zerbe et 
al., 2000). Impaired PMN functions predispose the dairy cows to develop mastitis, metritis, 
and other infectious diseases peripartally. Similarly, increased postpartal plasma NEFA 
concentration P 0.5 mEq / L increased the incidence of retained placenta in dairy cows by 80 
% (LeBlanc et al., 2004). Furthermore, in vitro incubation of lymphocytes culture with 
ketoacids impaired the proliferation of the lymphocytes (Franklin et al., 1991). 
Possible mechanism by which immune system might be involved in the etiology of the 
retained placenta is through the decreased expression of the interleukin-8 (IL-8) in the uteri 
of cows with fatty liver disease. IL-8 in the cotyledons of the uterus serves as a chemo-
attractant that direct the PMN to the cotyledons to initiate the detachment of the placenta. In 
dairy cows susceptible to retained placenta, IL-8 decreases, causing subsequent decrease in 
the chemotactic function of PMN (Kimura et al., 2002).     
Left Displacement of the Abomasum and Milk Fever 
Both left displacement of the abomasum (LDA) and milk fever like other fatty liver-
related health disorders have been associated strongly with fatty liver disease (Figure 1). 
Increased activity of hepatic aspartate-aminotransferase (AST), increase of plasma BHBA 
during early lactation, or BHBA of 0.2 mmol / L of milk were significantly associated 
positively with LDA development (Geishauser et al., 1997). Studies on plasma lipoprotein 
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lipids and apolipoprotein concentrations revealed that apolipoprotein-C (apo-C) decreases in 
dairy cows with fatty liver disease, LDA, milk fever, ketosis, and retained placenta 
(Yamamoto et al., 2001). Furthermore, plasma apo-C decreased precipitously in cows with 
milk fever, suggesting a strong role for apo-C in the etiology of milk fever and that apo-C 
might be used as a diagnostic marker for milk fever (Katoh and Nakagawa-Utah, 2001).    
Similarly, Yamamoto et al (2001) observed that concentrations of free cholesterol, 
cholesteryl esters, phospholipids, and apo-A-I in plasma and activity of lethicin: cholesterol 
acyltransferase (LCAT) decrease in dairy cows with fatty liver, ketosis, LDA, and retained 
placenta. Also, concentration of apo-B 100 decreased in dairy cows with LDA and ketosis 
(Oikawa et al., 1997). Thus, fatty liver is likely the primary etiology of the pathogenesis of 
LDA and possibly milk fever. 
Generally, cows that develop LDA have high plasma NEFA and ketone bodies and 
comparatively low feed intake, milk production, and plasma calcium (Van Winden et al., 
2003). In addition, prepartal plasma NEFA of P 0.5 mEq/L increased the likelihood that a 
dairy cow may develop LDA postpartum. However, postpartal plasma BHBA of P 1.2 mM or
milk BHBA of P 0.2 mM is considered more reliable measures than plasma NEFA in 
predicting the likelihood that a dairy cow might develop LDA postpartally (LeBlanc et al., 
2005).  
Whereas several risk factors are implicated in the etiology of LDA (Geishauser et al., 
2000a), one way fatty liver might induce LDA is through impairing the insulin function. 
Cows with fatty liver may experience insulin resistance that causes plasma insulin to rise 
above the normal physiological value for longer time (hyperinsulinemia). Consequently, 
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hyperinsulinemia decreases the rate of abomasum emptying, which may induce LDA 
(Holtenius and Traven, 1990).  
The peripartal DMI decline limits calcium intake and predisposes the dairy cow to 
develop hypocalcemia (milk fever). In addition, the postpartal partitioning of calcium to 
mammary gland to supply milk calcium further exacerbates the hypocalcemia. Clinical 
hypocalcemia diminish the smooth muscle tone of the uterus, teat sphincter, and the 
abomasum, facilitating development of the retained placenta, entry of the pathogens to the 
mammary gland to initiate mastitis, and development of LDA (Goff and Horst, 1997; Goff, 
2006). 
Reproductive Incompetence 
Fatty liver decreases the reproductive efficiency of dairy cows. Dairy cows that were over 
conditioned prepartally to induce fatty liver had high plasma NEFA concentration 
postpartally that was correlated highly with TAG accumulation in their livers. Moreover, 
increased hepatic TAG concentration positively correlated with the length of time to first 
ovulation (Rukkwamsuk et al., 1999). 
Research conducted to understand how fatty liver may impair the reproductive efficiency 
of dairy cows has elucidated that high plasma NEFA concentrations as a result of accelerated 
lipolysis increased the follicular fluid NEFA concentrations in the ovaries of fasted heifers 
(Jorritsma et al., 2003). The molecular mechanism by which increased NEFA concentration 
in the follicular fluid may impair the proliferation and differentiation of ovarian luteinizing 
granulosa cells and maturation of the oocysts is understood poorly. Data from research on 
mice, however, indicated that oleic acid prevented synthesis of steroid hormones in mouse 
Leydig cells by inhibiting cholesteryl esterase activity (Meikle, et al., 1996). Inhibition of 
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cholesteryl esterase prevents the hydrolysis of the cholesteryl esters to free cholesterol that 
could be utilized by the Leydig cells to produce steroid hormones. 
Role of Glycerol in Glucose and NEFA Homeostasis 
During the peripartal period, the dairy cow experiences an increased demand for glucose 
to support milk production. Increased glucose demand can be met through up-regulation of 
gluconeogenesis, increased supply of glucose precursors, or a combination of both. 
Insufficient glucose supply peripartally predisposes the dairy cow to develop NEB and thus 
to fatty liver and fatty liver-related metabolic and infectious health disorders.
Interest in using glucogenic precursors such as propylene glycol, propionate salts, and 
glycerol to overcome the NEB has increased. Existing data, however, do not support routine 
use of propylene glycol or propionate salts to alleviate the NEB or to treat fatty liver-ketosis 
complex (Overton and Waldron, 2004). 
Glycerol, also known as glycerin and less commonly as 1, 2, 3- propanetriol, enters the 
gluconeogenesis pathway after the reactions catalyzed by the rate-limiting enzymes pyruvate 
carboxylase (PC) and PEPCK. Therefore, glycerol could be a better gluconeogenic substrate 
(Goff and Horst, 2001).  
Remond et al (1993) reported that glycerol disappeared from the rumen within 4 hours 
after its oral administration. In the rumen of dairy cows, glycerol is fermented predominantly 
by Selenomonus ruminantium (Figure 2). Because Selenomonus bacteria are naturally present 
in rumen at relatively high concentrations, maximal degradation of glycerol is relatively fast. 
Furthermore, in ruminants, when administered as a drench, half of glycerol may produce 
glucose.  
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Figure 2. Metabolic use of glycerol. G-3-P, glyceraldehyde-3-phosphate; F-1,6-P2, 
fructose-1,6-bisphosphate; F-6-P, fructose-6-phosphate; G-6-P, glucose-6-phosphate; 
1,3-BPG, 1,3-bisphosphoglycerate; 3-PG, 3-phosphoglycerate; 2-PG, 2-
phosphoglycerate; PEP, phosphoenol pyruvate; TAG, triacylglycerols; VLDL, very low 
density lipoprotein. 
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Dietary supplemental glycerol decreases the proteolytic activity in the rumen by about 20 
%. Thus, glycerol seems to decrease the microbial breakdown of feed proteins in the rumen. 
This, in turn, increases the efficiency of protein utilization by the dairy cow (Paggi et al., 
1999). Glycerol treatment seems to improve the metabolic efficiency of dairy cows by 
decreasing the acetate to propionate ratio (DeFrain et al., 2004). Furthermore, feeding 
glycerol to dairy cows during the peripartal period decreased plasma NEFA concentration 
and increased milk production and milk protein (Bodarski et al., 2006). Drenching glycerol at 
1 L to dairy cows with resistant ketosis increased plasma glucose concentration and milk 
production and decreased ketone bodies in urine (Goff and Horst, 2001). However, because 
the microbial fermentation of glycerol in the rumen produces butyrate, which tends to 
increase plasma BHBA, the glucogenic value of the glycerol was questioned (Bodarski et al; 
Remond et al., 1993; DeFrain et al., 2004). 
We speculate that because the origin of the increased plasma BHBA, when glycerol is 
used, is the rumen fermentation, not the impaired TCA cycle, it seems that the increased 
plasma BHBA, when glycerol is used, is unrelated to the pathogenesis of ketosis. Therefore, 
the glucogenic capacity of the glycerol may be of therapeutic value. Furthermore, the 
increased milk yield observed by Bodarski et al (2006) and Goff and Horst (2001) may 
indicate an improved energy status elicited by feeding or drenching glycerol.   
Role of Glucagon in Glucose Homeostasis 
Glucagon is a 29-amino acid peptide hormone that is secreted primarily as proglucagon. 
Even though proglucagon is expressed in various tissues such as pancreas, intestine, and 
brain, it is processed differently into variant peptide hormones in a tissue-specific pattern 
(Figure 3). For instance, in the endocrine L-cells of the duodenum, proglucagon is  
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Figure 3. Proteolytic processing of proglucagon in the %-cells of the pancreas and L-cells 
of the duodenum. GRPP, glicentin-related pancreatic peptide; GLP-1, and -2, glucagon-
like peptide 1 and 2; PC-1, -2, and -3, prohormone convertases 1, 2, and 3; SP, signal 
peptide; IP, intervening peptide. Adapted from Holst 1997. 
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proteolytically processed by prohormone convertases 1 and 3 (PC-1 and -3) into glucagon-
like peptide 1 and 2 (GLP-1 and -2). In the B-cells of the islet of Langerhans in the pancreas, 
proglucagon is processed into functional glucagon hormone by PC-2 (Rouille et al., 1997). 
Glucagon is a key hormone of glucose homeostasis and is released into the bloodstream in a 
pulsatile fashion in response to low plasma glucose. Insulin decreases plasma glucose 
concentrations directly by signaling through the hepatic insulin receptor to inhibit 
gluconeogenesis and glycogenolysis. Also, insulin indirectly decreases plasma glucose 
concentration by decreasing the availability of the glucogenic substrates such as glycerol, 
alanine, and lactate from adipose tissues and muscles and increasing the uptake of glucose by 
the cells. On the other hand, glucagon stimulates hepatic glucose output by up-regulating 
gluconeogenesis and glycogenolysis and down-regulating glycolysis and glycogenesis 
(Figure 4). Thus glucagon is a counterregulator of insulin in maintaining glucose homeostasis 
(Fisher et al., 2003). 
Glucagon signals through its 7 transmembrance (7TM) receptor on the target cell surface 
(Figure 4). Binding of glucagon to its receptor induces conformational changes in the 
receptor that activate G proteins. However, two distinct classes of G proteins could be 
activated-- either Gq or GBs. Whereas activation of class GBs glucagon receptor promotes 
activation of cyclic-5Q-adenosine monophosphate (cAMP) through adenylate cyclase, 
however, activation of class Gq of glucagon receptor promote activation of phospholipase C, 
which catalyzes hydrolysis of phosphatidylinositol-4,5-biphosphate into diacylglycerol and 
inositol-1,4,5-triphosphate (IP3) to increase the concentration of  intracellular calcium ions. 
Increased IP3 mobilizes calcium from the endoplasmic reticulum and promotes influx of 
calcium through the L-type voltage-gated calcium channels localized in the plasma  
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Figure 4. Glucagon signaling pathway. PIP2, phosphatidylinositol-4,5-bisphosphate; 
PGC-1, peroxisome proliferator-activated receptor-coactivator-1; PEPCK, 
phosphoenolpyruvate carboxykinase; G-6-Pase, glucose-6-phosphatase. Adopted from 
Jiang and Zhang, 2003. 
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membrane. The increased intracellular calcium concentration is required to induce insulin 
secretion from J-cells in the islets of Langerhans in the pancreas to help increase the uptake 
of glucose by adipose and muscular tissues (Gromada et al., 1998). Thus, glucagons 
stimulates secretion of insulin either directly through PI3 or indirectly through increasing 
plasma glucose concentration. Increased concentration of intracellular cAMP as a result of 
activation of class GBs glucagon receptor induces activation of protein kinase A (PKA). 
Activated PKA provokes a phosphorylation cascade that activates phosphorylase kinase and 
phosphorylase to catalyze breakdown hepatic glycogen to first glucose-1-phosphate that is 
converted to glucose-6-phosphate (G-6-P) (Jiang and Zhang, 2003).  
PKA also activates glucose-6-phosphatase (G-6-Pase) through a process involving 
peroxisomes proliferator-activated receptor-R coactivator-1 (PGC-1). In turn, G-6-Pase 
dephosphorylates G-6-P, producing glucose that is released to the bloodstream (Jiang and 
Zhang, 2003). 
One way that glucagon up-regulates gluconeogenesis is by increasing the production of 
PEPCK. Beale et al (1984) reported that glucagon injection into rats increased the expression 
of PEPCK mRNA 9-fold within 30 to 45 minutes. The glucagon-activated PKA possibly 
activates PGC-1 by stimulating a cAMP-response element-binding (CREB) protein to bind a 
cAMP-responsive element in the promoter region of PGC-1 gene. Increased expression of 
PEPCK stimulates conversion of more OAA to phosphoenolpyruvate (PEP), resulting in 
more glucose being produced by gluconeogenesis (Jiang and Zhang, 2003).    
A crucial step for gluconeogenesis to proceed is the conversion of fructose-1,6-
bisphosphate (F-1,6-P2) to fructose-6-phosphate (F-6-P), which is catalyzed by fructose-1,6-
bisphosphatase-1 (F-1, 6-BPase).  Elevated concentration of fructose-2, 6-bisphosphate (F2, 
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6P2), however, inhibits F-1, 6-BPase, rendering gluconeogenesis inactive. The bifunctional 
enzyme phosphofructo kinase-2-/fructose-2, 6-bisphosphatase (PFK-2/F- 2,6-BPase) 
regulates the concentration of F-2, 6-P2. For example, PFK-2/F-2,6-BPase converts F-6-P to 
F-2, 6P2 by its tandem part PFK-2. However, F-2, 6-P2, when required, could be converted 
back to F-6-P by the other tandem part of the enzyme F-2, 6-BPase. 
Glucagon, through a cAMP phsophorylation cascade, activates PKA that phosphorylates 
PFK-2/F-2, 6-BPase (Figure 5). Phosphorylation induces concurrent inhibition of PFK-2 and 
activation of F-2, 6-BPase with concomitant conversion of F-2, 6-P2 to F-6-P. In turn, 
conversion of F-2, 6-P2 to F-6-P alleviates the inhibition on F-1, 6-BPase, resulting in more 
F-6-P being produced (Okar et al., 2004). Near the end of the gluconeogenesis pathway, 
hexose isomerase converts F-6-P into G-6-P. 
As mentioned earlier, glucagon up-regulates G-6-Pase through PGC-1. G-6-Pase 
catalyzes the conversion of the G-6-P that is produced by both glycogenolysis and 
gluconeogenesis pathways to glucose. Additionally, F-2, 6-P2 is an allosteric activator of 
PFK-1. As described above, glucagon activates F-2, 6-BPase that decreases F-2, 6-P2
concentration by dephosphorylating the C-2 position to produce F-6-P. Consequently, the 
decreased concentration of F-2, 6-P2 allosterically inactivates PFK-1. Thus, conversion of F-
6-P to F-1, 6-P2, a rate-limiting step in glycolysis, is inhibited (Figure 5). Overall, glucagon 
inhibits glycolysis, decreasing the consumption of glucose by peripheral tissues (Pilkis and 
Claus, 1991).  
At the conclusion of glycolysis, pyruvate kinase (PK) catalyzes the conversion of PEP to 
pyruvate and ATP. Glucagon may inactivate PK by two mechanisms. First, the glucagon-
activated PKA phosphorylates PK, rendering it more susceptible to be inhibited allosterically  
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Figure 5. Mechanisms by which glucagon regulates gluconeogensis and glycolysis. PFK-
1 and -2, phosphofructokinase-1 and -2; F-2,6-BP, fructose-2,6-bisphosphate; F-2,6-
BPase, fructose-2,6-bisphosphatase; F-6-P, fructose-6-phosphate; G-6-P, glucose-6-
phosphate; PKA, protein kinase A; PK, pyruvate kinase; PC, pyruvate carboxylase. 
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by alanine and by the abundance of ATP. Secondly, Pilkis and Claus (1991) reported that 
glucagon suppresses the transcription of PK gene and accelerates its mRNA degradation. 
Glucagon counteracts the action of insulin by increasing the expression of keygluconeogenic 
enzymes. Whereas expression of hepatic PEPCK mRNA was increased 9-fold within 30 to 
45 minutes by glucagon in diabetic rats, it was decreased 7- to 10-fold by insulin (Beale et 
al., 1984).   
Generally, glucagon stimulates protein degradation and inhibits protein synthesis. Amino 
acids stimulate protein synthesis by signaling through a protein kinase known as mammalian 
target of rapamycin (mTOR) (Kimball et al., 2004). In turn, mTOR phosphorylates an 
eukaryotic initiation factor 4E-binding protein (4E-BP1), ribosomal protein (rp), and S6 
kinase (S6K1). Phosphorylation of 4E-BP1 mediates the binding of mRNA to the 40S 
ribosomal subunit that initiates protein translation.       
Glucagon signal transduction activates PKA that represses phosphorylation of 4E-BP1 
and S6K1. Thus, glucagon prevents signaling for initiation of protein synthesis (Kimball et 
al., 2004) and instead promotes protein degradation by signaling through AMP-activated 
protein kinase that mediates its repressive action through phosphorylation of extracellular-
regulated kinase 1 (ERK1) and the rpS6 kinase p90rsk. Thus, glucagon stimulates the 
deamination of amino acids to be utilized as a carbon source for synthesis of glucose in the 
gluconeogenesis.  
In healthy dairy cows, continuous intravenous (IV) infusion of 10 mg/d of glucagon for 
14 days starting at d 21 postpartum increased plasma glucose and insulin. Contrary to that in 
nonruminants, glucagon did not increase lipolysis in adipose tissues (She et al., 1999). 
Consequently, Hippen et al (1999) showed that the most effective IV dose of glucagon that 
25
may improve the postpartal energy status of dairy cows without causing detrimental lipolytic 
and ketogenic effects is around 10 mg/d.  Furthermore, to evaluate the effects of exogenous 
glucagon on fatty liver disease, Hippen and colleagues (1999) overfed 20 multiparous dairy 
cows during the dry period to make them more susceptible to fatty liver disease and ketosis 
during the early postpartal period. Continuous IV infusion of 10 mg/d of glucagon for 14 
days starting at d 21 postpartum decreased the degree of fatty liver. 
Because IV infusion of glucagon is not practical in a dairy farm setting, Nafikov et al 
(2006) examined the efficacy of injecting glucagon subcutaneously three times per day to 
prevent development of fatty liver. Data indicated that subcutaneous injection of 15 mg/d of 
glucagon starting at d 2 postpartum and continuing for 14 days prevented fatty liver disease 
development in susceptible dairy cows. In a similar experiment, subcutaneous injection of 15 
mg/d of glucagon in dairy cows induced with experimental fatty liver starting at d 8 
postpartum cured fatty liver in dairy cows older than 3.5 years. More specifically, glucagon 
injection increased plasma glucose and insulin concentrations and decreased plasma NEFA 
concentration and hepatic TAG (Bobe et al., 2003). 
Gluconeogenesis 
Gluconeogenesis is the process that involves synthesis of glucose from noncarbohydrate, 
organic precursors such as propionate, pyruvate, lactate, glycerol, and most amino acids like 
alanine. Gluconeogenesis occurs mostly in the liver and to a lesser extent in the small 
intestine and kidney. Because most of the dietary carbohydrate entering the rumen is utilized 
by the rumen flora to maintain itself, propagate, or produce microbial protein, the 
gluconeogenesis is the primary source of glucose supply in the dairy cow (Reynolds et al., 
2003). In addition, the extremely little starch that escapes the rumen is hydrolyzed in the 
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doudenum by B-amylase to glucose that is utilized for energy by the entrocytes and other 
portal-drained viscera (i.e., intestine, pancreas, and omental adipose tissues) without making 
considerable contribution to milk lactose synthesis. Furthermore, total glucose flux from 
portal drained viscera is almost zero during the transition period (Freetly and Ferrell, 1998).  
In ruminants, the major substrate for the gluconeogenesis is the propionate that is 
produced in the rumen by microbial fermentation and contributes to about 70 % of total 
hepatic glucose produced by gluconeogenesis during the transition period. Propionate is 
converted to propionyl-CoA and then to succinyl-CoA that can be utilized by the TCA cycle 
in the mitochondria to produce OAA. Subsequently, in an exorgonic reaction, OAA can be 
decarboxylated by PEPCK to produce PEP, which can be transported to the cytosol and 
undergoes gluconeogenesis to produce glucose. 
Lactate, which is produced by the glycolysis in skeletal and uterine muscles, can be 
transported to the liver. In the liver, lactate is converted to pyruvate, which is utilized by 
gluconeogenesis to produce about 20 % of the net hepatic glucose output. Increase of glucose 
demand by the gravid uterus during late gestation increases gluconeogenesis from hepatic 
uptake of lactate released mainly by the uterus (Freetly and Ferrell, 1999). 
Glycerol is produced in abundance during the transition period by the hydrolysis of the 
adipose tissue TAG into NEFA and glycerol. Consequently, glycerol is exported to the liver 
where it is phosphorylated by glycerol kinase to B-glycerolphosphate (B-GP). Subsequently, 
B-GP is oxidized to by glycerolphosphate dehydrogenase to dihydroxyacetone phosphate 
(DHAP), which is converted to glyceraldehyde 3-phosphate (G-3-P) by the action of triose 
phosphate isomerase. Whereas NEFA do not contribute to glucose synthesis, G-3-P is a 
versatile molecule that can either be utilized in the gluconeogenesis to produce F-1, 6,-P2
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with subsequent glucose production or it can be converted to 1,3-bisphosphoglycerate (1,3-
BPG) and then to PEP in glycolysis. At the conclusion of glycolysis, PEP is converted to 
pyruvate with concomitant release of energy in the form of ATP. In addition, B-GP is used as 
a backbone for TAG synthesis. Overall, glycerol contributes about 4.0 % of net hepatic 
glucose synthesis during transition and early lactation periods (Reynolds et al., 2003). Only 
odd number fatty acids can produce propionyl-CoA that is able to be converted to glucose 
similar to propionate. 
Because amino acids are needed in relatively large amounts for milk protein synthesis 
and to supply essential amino acids required by the various tissues, amino acids contribute 
less than propionate to the net hepatic glucose synthesis (Freetly and Ferrell, 1998; Overton 
and Waldron, 2004). The major amino acid used by gluconeogenesis for glucose production 
is alanine, which is deaminated and converted to pyruvate by hepatic alanine transaminase 
before it can be utilized as a carbon source to synthesize about 8.0 % of net hepatic glucose 
output. Increasing the crude protein (CP) supply or the rumen undergradable protein (RUP) 
of prepartal dairy cow diet, however, did not improve the postpartal energy balance, decrease 
hepatic TAG content, or improve milk production (Greenfield et al., 2000). Furthermore, 
feeding higher RUP together with rumen-protected choline (RPC) to peripartal dairy cows 
decreased the expression of ornithine transcarbamylase mRNA, which codes for a key 
enzyme of the urea cycle and did not increase the expression of PEPCK or the 
argininosuccinate synthetase (AS) mRNA. Consequently, feeding excess protein to transition 
dairy cows could cause ammonia toxicity. Because feeding more RUP did not increase AS 
mRNA abundance, gluconeogenesis from amino acids possibly will be decreased as well 
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because the nitrogen that would be generated from the deamination of the amino acids before 
undergoing gluconeogenesis will not be removed efficiently (Hartwell et al., 2001).      
Prevention and Treatment of Fatty Liver Disease and Fatty Liver-Related Health 
Disorders 
The incidence of fatty liver and the other fatty liver-related peripartal health disorders in 
producing U.S. dairy herds causes tremendous losses to dairy industry (Bobe et al., 2004). 
Having only one of each of two cows calve without getting affected with one of the fatty 
liver-related peripartal health disorders is becoming a hard challenge to the dairy industry in 
the U.S. (Drackley et al., 2003). Different approaches have been aimed at either developing a 
preventative or a treatment of fatty liver and the other fatty liver-related health disorders. 
Manipulation of the Prepartal and Postpartal Dairy Cow Diets 
The first approach examined the prevention of the NEB by preventing the inherent drop 
of the prepartal DMI through force-feeding the refusals (Bertics et al., 1992). Force-feeding 
the refusals increased plasma glucose on d 2 prepartal and decreased liver TAG on d 1 
postpartum. Despite these changes, using high-energy prepartal diet to compensate for the 
peripartal DMI decline and to alleviate the ensuing NEB that would decrease the incidence of 
the peripartal diseases was not successful (Dewhurst et al., 2000; Rabelo et al., 2005). 
A second approach used low-energy, TMR diet throughout the dry-period to 
minimize over-conditioning during the dry period and to decrease postpartal plasma NEFA 
and hepatic TAG. The low-energy diet contained about 70 % chopped oat hay and supplied 
adequate metabolizable protein and 1.27 Mcal of NEL / kg of DM. Feeding a low-energy 
during the entire dry period did not decrease liver TAG or plasma NEF postpartum. 
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Furthermore, incidence of other fatty liver-related peripartal health disorders remained high 
(Grum et al., 1996). 
The effects of increasing the energy input by the postpartal diet or decreasing the energy 
output in the form of milk fat on improving the NEB postpartum was considered. 
Supplementing of the transition dairy cow diet with trans-10, cis-12 conjugated linoleic acid 
(CLA) to decrease milk fat production and thus enhance energy balance did not decrease 
plasma NEFA concentration postpartum (Castaneda et al., 2005). 
Because dietary long-chain fatty acids are absorbed directly as TAG lipoproteins into the 
lymphatic system and distributed to the peripheral tissues before reaching the liver, added 
dietary fat may provide energy to peripheral tissues during time of decreased DMI and thus 
decrease postpartal plasma NEFA concentration and prevent hepatic TAG accumulation. 
Feeding 454 g of the calcium salts of long-chain fatty acids from d 14 to d 24 postpartum to 
feed-restricted transition dairy cows, however, increased plasma NEFA and hepatic TAG and 
decreased hepatic TAG removal (Bertics et al., 1999). Additionally, to test whether 
increasing the energy density would increase the efficiency of the supplemental fat to 
decrease fatty liver and other fatty liver-related peripartal health disorders, Douglas et al 
(2004) fed three groups of cows a control diet moderately high in nonfiber carbohydrates 
(NFC), a diet low in NFC supplemented with fat, and a diet high in NFC supplemented with 
fat throughout the entire dry period. Regardless of the energy density, supplemental fat fed 
prepartally neither decreased hepatic lipid accumulation nor decreased incidence of fatty 
liver-related health disorders.  
The use of glucogenic precursors that might be utilized in gluconeogenesis to produce 
glucose to enhance the energy balance gave contradictory results. Whereas propylene glycol 
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drench on d 0 and d 1 postpartum increased milk production and decreased postpartal plasma 
NEFA concentration (Pickett et al., 2003) and hepatic TAG (Studer et al., 1993), it did not 
prevent development of the fatty liver-related peripartum health disorders or improve 
productivity and reproductivity of dairy cows (Hoedemaker et al., 2004; Juchem et al., 2004).
The use of different amounts of calcium propionate as a glucogenic precursor in the form 
of oral paste or mixed with the diet to increase the energy density of the diet gave 
inconsistent results. Although feeding 178 g/d propionate plus154 g/d calcium salt of long-
chain fatty acids to dairy cows during the transition period decreased plasma NEFA, it did 
not increase plasma glucose or insulin or decrease plasma BHBA (DeFrain et al., 2005).  In 
contrast, feeding calcium and chromium propionate increased DMI and lipogenesis and 
decrease lipolysis in the adipose tissue of transition dairy cows probably by increasing 
glucose uptake through chromium-stimulated insulin release (McNamara and Valdez, 2005). 
Furthermore, despite the observation that the calcium propionate supplement prevented milk 
fever in susceptible dairy cows, it did not prevent peripartal health disorders or improve 
productivity (Goff et al., 1996).  The use of either propionate or lactate by gluconeogenesis to 
synthesize glucose is in a state of balance. Therefore, propionate supplementation to increase 
glucose synthesis and improve the peripartal energy balance might spare the use of lactate as 
a glucogenic precursor without increasing the net synthesis of glucose (Reynolds et al., 2003)    
Use of a Metabolic Modulator 
Monensin, an ionophore, inhibits growth of gram-positive ruminal bacteria that produce 
acetate and methane and stimulates the growth of the gram-negative bacteria that produce 
propionate (e.g., Megasphera elsednii and Selenomonas ruminantium). Although it has been 
shown to improve energy balance (Duffield et al., 1998), trials designed to test the effects of 
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monensin on plasma glucose, NEFA, and BHBA concentrations when administered 
intraruminally or as a controlled-release capsules have shown discrepancy (Heuer et al., 
2001; Duffield et al., 2002; Bechett et al., 1998). Thus, considering the decrease of DMI 
peripartum, using monensin as a feed supplement to decrease fatty liver incidence might not 
be successful (Overton and Waldron, 2004). 
Use of VLDL Components to Enhance Hepatic TAG Disposal 
Choline, a vitamin-like nutrient, is a basic component of phosphatidylcholine. 
Phosphatidylcholine is essential for VLDL synthesis. Because VLDL synthesis and secretion 
is extremely slow in cows with fatty liver disease, it has been hypothesized that the sharp 
decline in peripartal DMI might limit nutrients such as choline needed for VLDL assembly 
and secretion (Piepenbrink and Overton, 2003) and thus may exacerbate hepatic TAG 
accumulation. Feeding of rumen-protected choline to dairy cows peripartally neither 
decreased plasma NEFA and hepatic TAG (Piepenbrink and Overton, 2004) nor affected 
hepatic lipid metabolism. Moreover, plasma cholesterol and phospholipids remained 
unchanged (Janovick-Guretzky et al., 2006). Hepatocyte growth factor (HGF) is a 
polypeptide cytokine that has been shown to ameliorate fatty liver disease by upregulating 
MTP and ApoB and increasing secretion of TAG from the liver (Kosone et al, 2007). 
However, oncogenesis and hyperlipidemia are thought to be a complication of HGF 
administration (Horiguchi et al., 2002). 
Use of Hormones 
Different hormones have been used to improve the energy balance and prevent the 
peripartal health disorders through increasing plasma glucose concentration such as 
glucagon, which was discussed earlier, insulin, and bovine somatotropin (bST). To determine 
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the appropriate dose of slow-release insulin (SRI) that would decrease plasma NEFA and 
hepatic TAG without decreasing plasma glucose concentrations, Hayirli et al (2002) injected 
dairy cows with different concentrations of SRI on d 3 postpartum. Despite the increase of 
DMI and milk yield, SRI decreased plasma glucose more precipitously than plasma NEFA 
and induced hypoglycemic shock to some cows. An explanation of this could be that directly 
after parturition lipolysis may be resistant to the effect of insulin.  
Bovine somatotropin is synthesized and secreted by the somatotroph cells of the anterior 
pituitary gland. The physiological role of bST in metabolism is carried out either directly on 
the adipocytes by stimulating lipolysis and inhibiting lipogenesis or indirectly by stimulating 
the release of insulin-like growth factor from the hepatocytes. Although administration of 
bST to dairy cows during early lactation increased milk production by 20 %, it failed to 
increase expression of the gluconeogenic enzymes PC or PEPCK. Similarly, bST 
administration during early lactation increased hepatic TAG and did not decrease plasma 
NEFA and BHBA or increase plasma glucose (Pershing et al., 2002). Therefore, the co-
administration of glucagon and glycerol as a glucogenic substrate that could be utilized in 
gluconeogenesis to synthesize glucose, glycolysis to produce ATP, or as a backbone to 
facilitate liver NEFA removal seems a better alternative.  
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CHAPTER 2. ACUTE METABOLIC RESPONSES OF TRANSITION 
DAIRY COWS WITH FATTY LIVER DISEASE TO SUBCUTANEOUS 
GLUCAGON INJECTIONS, ORAL GLYCEROL, OR BOTH 
 
A paper to be submitted to the Journal of Dairy Science 
 
M. A. Osman, P. S. Allen, N. A. Mehyar, G. Bobe, J. F. Coetzee, K. Koehler, and D. C. Beitz 
 
ABSTRACT 
This study examined the effects of multiple subcutaneous glucagon injections with or 
without co-administration of oral glycerol on energy status-related blood metabolites and 
hormones of Holstein dairy cows in the first two wks postpartum. Twenty multiparous cows 
were fed a dry cow ration supplemented with 6 kg of cracked corn during the dry period to 
increase the likelihood of developing postpartal fatty liver disease. Cows with a body 
condition score of P 3.5 points (1-5 point scale) were assigned randomly to one of four 
treatment groups: saline, glucagon, glucagon plus glycerol, and glycerol. Following 
treatment, serial blood samples were collected over an 8-hr period to determine the effects of 
glucagon and/or glycerol on blood metabolites and hormones. Treatment effects were 
determined by comparing the concentration of metabolites and hormones during the 8-hr 
period after treatment administration (time 0) with the concentration of the same compounds 
at time zero on d 1, d 7, and d 13 postpartum. Glucagon alone tended to increase 
concentrations of plasma glucose on d 7 and d 13 postpartum (P = 0.07 and P = 0.06,
respectively) and glucagon on d 13 (P= 0.08), and increased insulin on d 1 and d 7 (P = 0.04
and P = 0.01, respectively) and decreased concentrations of plasma nonesterified fatty acids 
(NEFA) on d 13 postpartum (P = 0.04) relative to the saline. Administration of glucagon 
plus glycerol increased and sustained postpartal plasma glucose on d1, d 7, and d 13 (P =
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0.0006, P = 0.0008, and P = 0.02, respectively), glucagon on d 1 and d 7(P = 0.03 and P =
0.05, respectively), insulin on d 1, d 7, and d 13 (P = 0.002, P = 0.0004, and P = 0.01,
respectively), and decreased plasma NEFA on d 13 (P = 0.01) and J-hydroxybutyrate 
(BHBA) on d 1 and d 7 (P = 0.05, and P = 0.03, respectively).  Interestingly, administration 
of glycerol alone decreased postpartal plasma NEFA on d 1, d 7, and d 13 (P = 0.03, P =
0.05, and P = 0.0002, respectively), BHBA on d 1 (P = 0.02), and increased triacylglycerol 
(TAG) on d 13 postpartum (P = 0.04). Early postpartal treatment of dairy cows with 
glucagon plus glycerol increased plasma glucose and insulin, decreased plasma NEFA and 
BHBA, and increased secretion of liver NEFA as plasma TAG. These responses suggest that 
glucagon and glycerol act additively when co-administered to decrease the likelihood of 
energy status-related diseases development in dairy cows.  
INTRODUCTION 
Fatty liver disease (FLD) affects dairy cows in the late prepartal and early postpartal 
periods up to 4 wk postpartum (Grummer, 1993). The severity of FLD is often classified on 
the basis of the percentage of accumulated triacylglycerols (TAG) in the liver (Uchida et al., 
1992; Bobe et al., 2004) to assess the potential for deleterious effects to the health, 
productivity, and reproductivity of dairy cows. 
During the peripartal period, dry matter intake (DMI) by dairy cows spontaneously 
declines. Regardless of the energy density and protein content of the peripartal diet, DMI 
decreases by about 30 % during the final three wk prepartum and about 90 % of that DMI 
decrease happens during the last wk (Doepel et al., 2002; Bertics et al., 1992; Hayirli et al., 
2002). Because the sharp decrease in DMI is accompanied with an increased peripartal 
35
energy and nutrient requirement by the gravid uterus and by the mammary gland to initiate 
lactogenesis (Goff and Horst, 1997), dairy cow develops negative energy balance (NEB) that  
reaches -16 Mcal/d (Doepel et al., 2002). To compensate for the NEB, the dairy cow 
mobilizes body fat reserves in the form of NEFA and glycerol. Furthermore, NEFA are taken 
up mainly by liver and either oxidized in the mitochondria to produce energy or exported in 
the form of TAG-rich very low density lipoprotein. FLD develops in different degrees when 
uptake of NEFA by the liver far exceeds their disposal through oxidation or export as TAG-
rich very low density lipoprotein (Grummer, 1993).  
FLD is considered the number one risk factor for ketosis development in dairy cows 
(Veenhuizen et al., 1991). Furthermore, FLD impairs the immune system during the 
peripartal period making the dairy cow especially vulnerable to develop mastitis, 
endometritis (Zerbe et al., 2000), and retained placenta (Kimura et al., 2002; LeBlanc et al., 
2005). In addition, FLD is associated intimately with left displacement of the abomasum and 
milk fever (Yamamoto et al., 2001; Katoh and Nakagawa-Utah, 2001) and implicated with 
decreased reproductive health of dairy cow (Jorritsma et al., 2003). 
Attempts to use nutritional means to alleviate the peripartal NEB and prevent the 
development of FLD during the postpartal period either through the use of low-energy 
prepartal diet (Grum et al., 1996) or the increase of the energy supply by the diet and the 
decrease of the energy output by decreasing milk fat (Castaneda et al., 2005; Douglas et al., 
2004) were not as successful. Similarly, the use of the glucogenic precursors such as 
propylene glycol, propionate salts, and amino acids gave inconsistent results (Hoedemaker et 
al., 2004; Juchem et al., 2004; Goff et al., 1996; Greenfield et al., 2000). In addition, the use 
of slow-release insulin on d 3 postpartal decreased plasma glucose more precipitously than 
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plasma NEFA, causing hypoglycemic shock to some experimental cows (Hayirli et al., 
2002).  
Injection of Holstein dairy cows with experimental FLD subcutaneously with 15 mg/d of 
glucagon for 14 d during the postpartal period increased plasma glucose and insulin, 
decreased plasma NEFA and hepatic TAG, and prevented and cured FLD (Bobe et al., 
2003c; Nafikov et al., 2006). One metabolic pathway by which glucagon cures FLD is by up-
regulating gluconeogenesis and increasing plasma glucose concentrations (Hippen et al., 
1999b). Because the DMI decreases during the peripartal period, gluconeogenic substrates 
might be in a short supply. Glycerol is metabolized in the rumen and liver to intermediates of 
gluconeogenesis and glycolysis (Remond et al., 1993; Goff and Horst, 2001) with potential to 
alleviate the peripartal NEB. Therefore, we hypothesized that when postpartally co-
administered, glucagon and glycerol may act additively to alleviate the peripartal NEB and 
treat FLD in dairy cows. Thus, the objectives of this study were to examine how glucagon 
and glycerol might act additively to treat FLD and to understand the biochemical 
mechanisms whereby this additiveness could take place. The ultimate goal of this study is to 
provide the U.S. farmers with a slow-release subcutaneous implant of glucagon and/or a 
glycerol feeding protocol as an effective tool for treating fatty liver disease in dairy cows.   
MATERIALS AND METHODS 
Experimental Design 
Twenty multiparous Holstein dairy cows from the Iowa State University dairy herd were 
selected during the dry period to participate in the study, based on parity and a BCS of 3.5 or 
larger. Cows were assigned randomly to one of four treatment groups—saline (control), 
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glucagon, glycerol, or glucagon plus glycerol. Starting at 6 wk prepartum, cows were housed 
in straw-bedded free stall and offered ad libitum a dry cow TMR diet based on NRC 
recommendation (NRC, 2001) that was supplemented with 6 kg of cracked corn (Bobe et al., 
2003b) to induce FLD development postpartum. Additionally, cows were offered grass hay 
ad libitum. During the prepartal period, all experimental cows were inspected daily for signs 
of impending parturition such as udder distension, edema of external genitalia, and vaginal 
discharge to avoid having prepartal liver biopsy not taken because a cow calved earlier than 
projected. Moreover, experimental cows received a physical examination weekly during the 
prepartal period and daily during the postpartal period. Details of physical examinations 
included measuring the heart rate, respiratory rate, ruminal movements, urinary ketones, 
fecal consistency, rectal temperature, BCS, and signs of lameness. Furthermore, a test for 
detection of abomasum displacement was included during the postpartal period.  
Starting on d 0 postpartum, experimental cows were housed in a sand-bedded tie stall and 
offered twice a day an NRC (2001) recommended TMR for high producing dairy cows at 
9:00 h and 15:00 h. Furthermore, treatment administration was started on d 0 postpartum, 4 h 
after parturition. Control group cows (n = 4) received 60 mL of 0.9 % sodium chloride (pH 
10.25) under the skin of the neck each 8 h daily for 14 d. Glucagon group cows (n = 4) 
received 5 mg of glucagon (donated by Eli Lilly and Co., Indianapolis) dissolved in 60 mL of 
0.9 % sodium chloride (pH 10.25) and injected under the skin of the neck each 8 h for 13 d, 
16 h apart on d 14, and a single injection on d 15 postpartum. Glycerol group cows (n = 6) 
received orally 400 mL of pure glycerol (West Central Inc., Ralston, IA) diluted with 100 mL 
of water once a day at 6:00 h for 14 d. Glucagon plus glycerol group cows (n = 6) received 
both treatments as described above. Glucagon solutions were prepared in autoclaved 
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glassware that was pre-rinsed by 1 % BSA (cat. number A8327, Sigma, St. Louis, MO, USA) 
and kept at 4 °C for no more than 36 h. All the experimental and surgical procedures were 
done in accordance with the guidelines of the Iowa State University Committee on Animal 
Care. 
Sampling and Analysis 
Blood. To monitor the acute effects of glucagon and glycerol on blood hormones and 
metabolites, blood samples were collected on d 1, d 7, and d 13 postpartum by using a 
jugular catheter (cat number GAS65, Abbott, Redwood City, CA) at -15, -10, -5, 15, 30, 45, 
60, 80, 100, 120, 150, 180, 210, 240, 300, 360, 420, and 480 min relative to each treatment 
administration. Twenty milliliters of blood were collected into two vacautainer tubes (Tyco 
Health Care Group LP, Mansfield, MA) containing Na2-EDTA and placed on ice until 
plasma was separated by centrifugation at 500 x g for 20 min at 4°C. Harvested plasma was 
stored at – 20°C until analyzed for concentrations of glucose (kit number G7519-500, Pointe 
Scientific Inc., Canton, MI), NEFA (NEFA C kit number 994-75409, Wako, Richmond, 
VA), BHBA (kit number H7587-58, Pointe Scientific Inc., Canton, MI), PUN (kit number 
B7551-120, Pointe Scientific Inc., Canton, MI), and TAG (kit number T7532-120, Pointe 
Scientific Inc, Canton, MI) adapted for the microplate reader (SPECTRA Max PLUS, 
Sunnyvale, CA). For plasma hormones determination, 1 mL of plasma was mixed with 500 
KIU of aprotinin (Boehringer-Mannheim, Indianapolis, IN) and analyzed for plasma 
glucagon and insulin concentrations (kit number GL-32K and PI-12K, Linco Research Inc., 
St. Louis, MO). 
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Statistical Analysis 
The dependent variable was the change of the response variable (plasma glucagon, 
glucose, insulin, NEFA, BHBA, PUN, and TAG) from baseline concentrations (-15, -10, and 
–5 min before glucagon and/or glycerol administration) to the concentrations after glucagon 
and/or glycerol administration (15, 30, 45, 60, 80, 100, 120, 150, 180, 210, 240, 300, 360, 
420, and 480 min after glucagon and/or glycerol administration).  For all plasma metabolites 
a response, the change was calculated from log-transformed concentrations because the 
statistical model would not converge using the non-transformed values.  The fixed effects 
were treatment (Saline, Glucagon, Glycerol, Glucagon plus glycerol), day of administration 
(d1, d7, d13), time after treatment administration (15, 30, 45, 60, 80, 100, 120, 150, 180, 210, 
240, 300, 360, 420, or 480 min), and their two-way interactions.  The Kronecker product of a 
completely unrestricted variance-covariance matrix (for day of administration) and a first 
order autoregressive variance-covariance matrix (for time after administration) was used to 
account for double repeated measures taken on individual cows across time.   
The overall effects of glucagon, glycerol, and glucagon plus glycerol administration were 
evaluated by comparing their estimated changes from baseline concentrations averaged 
across time after injection (15-480 min) with the corresponding estimated change of the 
Saline group using a student t-test in the ESTIMATE statement. The average effects of 
glucagon, glycerol, and glucagon plus glycerol administration for the 8-h post-injection 
period were evaluated by calculating the area under the curve minus the area below the 
baseline concentration by using the trapezoidal rule (Granville et al., 1941) divided through 
480 min.  The estimated average areas of glucagon, glycerol, and glucagon plus glycerol 
administration were compared with the corresponding average area of the Saline group using 
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a student t-test in the ESTIMATE statement.  To obtain the correct degrees of freedom the 
KENWARDROGER option was invoked that uses the Satterthwaite adjustment for degrees 
of freedom with a Kenward-Roger adjustment on standard errors (Tempelman et al., 2002).  
Means and SEMs presented in figures are raw means and SEMs.  All statistical tests were 
two-sided.  Significance was declared at P O 0.05 and tendency toward significance was 
declared at P O 0.09. 
RESULTS 
Plasma Constituents 
Plasma Glucagon. To verify that injected glucagon treatment increased plasma glucagon 
concentrations, the glucagon content of blood sampled during an 8-hour period was 
determined on d 1, d 7, and d 13 postpartum. Taken as a whole, we detected a significant 
effect (P = 0.004) of treatment on plasma glucagon concentrations during the treatment 
period. Effects of day and interaction of treatment × day, however, were not significant (P =
0.87 and P = 0.93, respectively; Figures 1A, 1B, and 1C). Specifically, plasma glucagon 
concentrations acutely increased (P = 0.03 and P = 0.05; Figures 1A and 1B) on d 1 and d 7 
postpartum, respectively, in cows given the glucagon plus glycerol treatment. Glucagon plus 
glycerol treatment, however, did not significantly increase (P = 0.28; Figure 1C) plasma 
glucagon concentration on d 13 postpartum. Equally, glucagon treatment did not significantly 
increase (P = 0.10 and P = 0.14; Figures 1A and 1B) plasma glucagon on d 1 and d 7 
postpartum, respectively. But, a tendency (P = 0.08; Figure 1C) for plasma glucagon 
concentration to increase by the glucagon treatment was observed on d 13 postpartum. 
Conversely, the glycerol treatment did not affect plasma glucagon concentrations  
41
-50 0 50 100 150 200 250 300 350 400 450 500
100
200
300
400
500
600
700
800 A
P l
a s
m
a
g l
u c
a g
o n
d
1 ,
p g
/ m
L
Saline
Glucagon
Glycerol
GlucGlyc
-50 0 50 100 150 200 250 300 350 400 450 500
100
200
300
400
500
600
700
800 B
P l
a s
m
a
g l
u c
a g
o n
d
7 ,
p g
/ m
L
Time relative to treatment, min
Saline
Glucagon
Glycerol
GlucGlyc
 
-50 0 50 100 150 200 250 300 350 400 450 500
100
200
300
400
500
600
700
800
C
Pl
as
m
a
gl
uc
ag
on
d
13
,p
g/
m
L
Time relative to treatment, min
Saline
Glucagon
Glycerol
GlucGlyc
 
Figure 1. Plasma glucagon concentrations of cows treated with saline, glucagon, 
glycerol, or glucagon plus glycerol on d 1, d 7, and d 13 postpartum. Panel A, whereas 
glucagon and glycerol effects did not differ (P = 0.69 and P = 0.10, respectively; SEM = 
0.32 to 0.35), glucagon plus glycerol effects significantly differed (P = 0.03; SEM = 0.33). 
Panel B, glucagon and glycerol effects did not differ (P = 0.14 and P = 0.72, respectively; 
SEM = 0.27 to 0.28), but glucagon plus glycerol effects continued to be different (P =
0.05; SEM = 0.26). Panel C, glycerol and glucagon plus glycerol effects did not differ (P
= 0.72 and P = 0.28, respectively; SEM = 0.32 to 0.33), however, glucagon effects tended 
to be different (P = 0.08; SEM = 0.35). On the whole, effect of treatment was significant 
(P = 0.004), but effects of day (P = 0.87) and day × treatment interaction (P = 0.93) were 
not significant.  
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significantly (P= 0.69, P = 0.72, and P = 0.72; Figures 1A, 1B, and 1C) on d 1, d 7, and d 13 
postpartum, respectively.  
Plasma Glucose. Overall, effects of treatment on plasma glucose concentrations was 
significant (P = 0.0001). There were no effects (P = 0.1 and P = 0.47) of day or interaction of 
the treatment × day on plasma glucose concentration. The acute effect of each treatment on 
plasma glucose concentrations was examined during the postpartal period. Plasma glucose 
concentrations tended to increased acutely (P = 0.07 and P = 0.06; Figures 2B and 2C) in 
cows given the glucagon treatment on d 7 and d 13 postpartum, respectively. Plasma glucose 
concentration, however, did not increase (P = 0.85; Figure 2C) because of glucagon 
treatment on d 1 postpartum. In contrast, administration of glucagon plus glycerol increased 
(P = 0.006, P = 0.008, and P = 0.02; Figures 2A, 2B, and 2C) plasma glucose concentrations 
on d 1, d 7, and d 13 postpartum, respectively. On the other hand, the glycerol treatment did 
not cause plasma glucose concentrations to increase (P = 0.53, P = 0.46 and P = 0.76;
Figures 1A, 2A, and 2B) on d 1, d 7, and d 13 postpartum, respectively.  
Plasma Insulin. In general terms, significance effects of treatment (P = 0.0002), day (P =
0.02), and treatment × day (P = 0.02) on plasma insulin concentrations were detected. More 
precisely, plasma insulin concentrations acutely increased (P = 0.002, P = 0.0004, and P=
0.01; Figures 3A, 3B, and 3C) in cows given the glucagon plus glycerol treatment on d 1, d 
7, and d 13 postpartum, respectively. Similarly, glucagon treatment acutely increased (P =
0.04, P = 0.01; Figures 3B and 3C) plasma insulin concentrations on d 1 and d 7 postpartum, 
respectively, but not on d 13 postpartum (P = 0.20; Figure 3B). In contrast, no effect (P =
0.73, P = 0.65, and P = 0.73; Figures 3A, 3B, and 3C) of glycerol treatment on plasma 
insulin concentrations was detected on d 1, d 7, or d 13 postpartum, respectively.   
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Figure 2. Plasma glucose of cows treated with saline, glucagon, glycerol, or glucagon 
plus glycerol on d 1, d 7, and d 13 postpartum. Panel A, glucagon and glycerol effects 
were not significant (P = 0.85 and P = 0.53, respectively; SEM = 0.08), but glucagon plus 
glycerol effect was highly significant (P = 0.006; SEM = 0.08). Panel B, effect of glycerol 
was not significant (P = 0.46; SEM = 0.08), effect of glucagon tended to be significant (P
= 0.07; SEM = 0.08), and effect of glucagon plus glycerol was highly significant (P =
0.0008; SEM = 0.08). Panel C, similarly, whereas glycerol effect continued to be 
insignificant (P = 0.77; SEM = 0.09), glucagon effect approached significance (P = 0.06;
SEM = 0.09), and glucagon plus glycerol effect was significant (P = 0.02; SEM = 0.08). 
Largely,  effect of treatment was significant (P = 0.0001), but effects of day and the 
interaction of day × treatment were not significant (P = 0.10 and P = 0.47, respectively) 
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Figure 3. Plasma insulin concentrations of cows treated with saline, glucagon, glycerol, 
or glucagon plus glycerol on d 1, d 7, and d 13 postpartum. Panel A, glucagon and 
glucagon plus glycerol effects differed (P = 0.04 and P = 0.001, respectively; SEM = 0.17 
to 0.18), but glycerol effect did not differ (P = 0.73; SEM = 0.17). Panel B, effect of 
glycerol remained to be indifferent (P = 0.65; SEM = 0.14). However, glucagon and 
glucagon plus glycerol effects significantly differed (P = 0.01 and P = 0.0004; SEM = 
0.15).  Panel C, effects of glucagon and glycerol did not differ (P = 0.20 and P = 0.73;
SEM = 0.25 to 0.27), but glucagon plus glycerol effect was significantly different (P =
0.01; SEM = 0.25). Overall, effect of treatment, day, and the interaction of day × 
treatment were significant (P = 0.0002, P = 0.02, and P = 0.02, respectively).  
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Plasma NEFA. Overall, we observed a significant effect (P = 0.01) of treatment on 
plasma NEFA concentrations during the treatment period. In contrast, effects of the day and 
the interaction of the day × treatment were not significant (P = 0.10 and P = 0.30,
respectively). Despite the numerical decrease, glucagon administration had no significant 
effects (P = 0.80 and P = 0.30; Figures 4A and 4B) on plasma NEFA concentration on d 1 
and d 7 postpartum, respectively. On the contrary, glucagon administration on d 13 
postpartum caused plasma NEFA concentrations to decline acutely (P = 0.04; Figure 4C). 
Similarly, glucagon plus glycerol treatment decreased (P = 0.01; Figure 4A) plasma NEFA 
concentration on d 13 postpartum but not (P = 0.37 and P = 0.14; Figures 4A and 4B) on d 1 
and d 7 postpartum, respectively. As shown in Figures 4A, 4B, and 4C, glycerol 
administration significantly decreased (P = 0.03, P = 0.05, and P = 0.0002) plasma NEFA 
concentrations on d 1, d 7, and d 13 postpartum, respectively. 
Plasma BHBA. Largely, the effect of treatment on plasma BHBA was significant (P =
0.03). Effects of the day and the interaction of the day × treatment were not significant (P =
0.47 and P = 0.12). In particular, glucagon plus glycerol treatment acutely decreased (P =
0.05 and P = 0.03; Figures 5A and 5B) plasma BHBA concentrations on d 1 and d 7 
postpartum, respectively. Glucagon plus glycerol treatment, however, did not alter (P = 0.52;
Figure 5C) plasma BHBA on d 13 postpartum. Glycerol treatment, on the other hand, acutely 
decreased (P = 0.02; Figure 5A) plasma BHBA concentration on d 1 postpartum. Yet, 
glycerol administration on d 7 and d 13 postpartum did not vary (P = 0.13 and P = 0.36;
Figures 5B and 5C, respectively. Glucagon alone caused no change (P = 0.30, P = 0.71, and 
P = 0.50; Figures 5A, 5B, and 5C) in plasma BHBA concentration on d 1, d 7, and d 13 
postpartum, respectively.  
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Figure 4. Plasma NEFA concentrations of cows treated with saline, glucagon, glycerol, 
or glucagon plus glycerol on d 1, d7, and d 13 postpartum. Panel A, glucagon and 
glucagon plus glycerol effects were not significant (P = 0.80 and P = 0.37, respectively; 
SEM = 0.30 to 0.31). On the contrary, glycerol effect was significant (P = 0.03; SEM = 
0.30). Panel B, whereas glucagon and glucagon plus glycerol effects continued to be 
insignificant (P = 0.30 and P = 0.14, respectively; SEM = 0.20 to 0.26), glycerol effect 
was significant (P = 0.05; SEM = 0.16). Panel C, glucagon, glycerol, and glucagon plus 
glycerol effects were significant (P = 0.04, P = 0.0002, and P = 0.01, respectively; SEM = 
0.17 to 0.19).  Generally, effect of treatment was significant (P = 0.01), but effects of day 
and the interaction of treatment × day were not significant (P = 0.10 and P = 0.30,
respectively). 
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Figure 5. Plasma BHBA concentrations of cows treated with saline, glucagon, glycerol, 
or glucagon plus glycerol on d 1, d 7, and d 13 postpartum. Panel A, glucagon effect was 
not different (P = 0.30; SEM = 0.11), however, glycerol and glucagon plus glycerol 
effects were different (P = 0.02 and P = 0.05, respectively; SEM = 0.10 to 0.11). Panel B, 
glucagon and glycerol effects were not different (P = 0.71 and P = 0.13, respectively; 
SEM = 0.13 to 0.14), but glucagon plus glycerol effect was different (P = 0.03; SEM = 
0.13). Panel C, no treatment effects were detected (P G 0.37; SEM = 0.11). Taken as a 
whole, effect of treatment was significant (P = 0.03). In contrast, effects of day and 
interaction of treatment × day were not different (P = 0.47 and P = 0.12, respectively). 
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Plasma TAG. Taken as a whole, there was a significant (P = 0.04) treatment effect on 
postpartal plasma TAG concentrations. The effects of day and interaction of the treatment × 
day, however, were not significant (P = 0.19 and P = 0.55, respectively). Importantly, plasma 
TAG concentrations were increased acutely (P = 0.04; Figure 6C) in cows given the glycerol 
treatment on d 13 postpartum and were not changed (P = 0.16 and P = 0.80; Figures 6A and 
6B) on d 1 and d 7 postpartum, respectively. In contrast, glucagon and glucagon plus glycerol 
treatments did not alter (P P 0.14; Figures 6A, 6B, and 6C) plasma TAG concentrations on d 
1, d 7, and d 13 postpartum. However, the glucagon plus glycerol treatment numerically 
increase plasma TAG concentrations on d 1 and d 7 postpartum (Figures 6A and 6B). 
To verify whether glycerol facilitates the rapid removal of liver NEFA, the Pearson’s 
coefficient for the correlation between plasma NEFA and TAG concentrations was 
calculated. In the glucagon plus glycerol-treated cows, the Pearson’s coefficient for the 
correlation was -0.28 on d 1 postpartum and tended (P =0.08) to be significant. In the 
glucagon-treated group, the Pearson’s coefficient for the correlation between plasma NEFA 
and TAG concentrations was 0.71 (P = 0.0001) and 0.78 (P = 0.0001) on d 1 and d 7 
postpartum, respectively.  
Plasma Urea N. The overall effects of treatment, day, and day × treatment on PUN were 
not significant (P = 0.70, P = 0.13, and P = 0.10, respectively). Administration of glucagon 
alone, glycerol alone, or the tow combined did not seem to alter (P P 0.20; Figures 7A, 7B, 
and 7C) plasma urea N concentrations either on d 1, d 7, or d 13 postpartum. 
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Figure 6. Plasma TAG concentrations of cows treated with saline, glucagon, glycerol, or 
glucagon plus glycerol on d 1, d 7, and d 13 postpartum. Panel A, glucagon, glycerol, 
and glucagon plus glycerol effects were not significant (P G 0.14; SEM = 4.3 to 4.8). 
Panel B, glucagon, glycerol, and glucagon plus glycerol effects were not significant (P G
0.56; SEM = 1.6 to 1.8). Panel C, whereas glucagon and glucagon plus glycerol effects 
continued to be insignificant (P = 0.89 and P = 0.25, respectively; SEM = 1.5 to 1.7), 
glycerol effect was significant (P = 0.40; SEM = 1.6). Overall, effect of treatment was 
significant (P = 0.04), but effect of day and interaction of treatment × day were not 
significant (P = 0.20 and P = 0.55, respectively). 
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Figure 6. Plasma urea N concentrations of cows treated with saline, glucagon, glycerol, 
or glucagon plus glycerol on d 1, d 7, and d 13 postpartum. Panel A. glucagon, glycerol, 
and glucagon plus glycerol effects were not different (P G 0.23; SEM = 0.11 to 0.12). 
Panel B, glucagon, glycerol, and glucagon plus glycerol effects were not different (P G
0.32; SEM = 0.34 to 0.37). Panel C, glucagon, glycerol, and glucagon plus glycerol 
effects were not different (P G 0.42; SEM = 2.0 to 2.2). Generally, effects of treatment, 
day, and interaction of treatment × day were not significant (P G 0.13).  
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DISCUSSION 
The objective of the present study was to examine whether glucagon and glycerol, when 
co-administered, might act additively to decrease the peripartal NEB in Holstein dairy cows 
induced with experimental FLD. Precisely, we wanted to understand and elucidate the 
biochemical mechanisms whereby glucagon and glycerol might improve the peripartal 
energy balance and treat fatty liver disease.   
Because DMI decreases (Bertics et al., 1992; Doepel et al., 2002) during the peripartal 
period, dietary glucogenic amino acids and propionate from rumen fermentation might 
become in short supply. Furthermore, the need for amino acids to support postpartal 
colostrum and milk protein might lessen their contribution to net hepatic glucose synthesis 
(Freetly and Ferrell, 1998; Overton and Waldron, 2004).   
Therefore, gluconeogenesis might be deprived of suitable amount of substrates. 
Subsequently, plasma glucose concentrations would be inadequate and the dairy cow will 
develop NEB and FLD. Therefore, the rationale for using glycerol as a glucogenic precursor 
in this study was based on the assumption that, whereas other gluconeogenic substrates are in 
a short supply during the peripartal period, a more versatile intermediate such as 
glyceraldehyde-3-phosphate (G-3-P) might be needed to keep both the gluconeogenesis and 
glycolysis accelerated.  
In this study, administration of glucagon alone or glucagon plus glycerol starting on d 0 
postpartum acutely increased plasma glucagon concentrations to about 700 pg/mL within 15 
min (Figures 1A, 1B, and 1C) on d 1, d 7, and d 13 postpartum, which is consistent with 
previous results (Bobe et al., 2003a; Hippen et al., 1999a; She et al., 1999b). These results 
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further corroborate an earlier finding that the subcutaneous route is reliable for glucagon 
administration and produces reproducible results. 
Plasma glucose concentration was increased by glucagon plus glycerol but not by 
glucagon alone on d 1 postpartum (Figure 2A). Inadequate postpartal liver glycogen probably 
impeded the ability of glucagon to increase plasma glucose. It is possible that most of 
glycogen was converted to glucose to support milk lactose synthesis. Additionally, the 
inadequate peripartal DMI coupled with the need to partition amino acids to support 
colostrum and milk protein synthesis probably deprived gluconeogenesis of a suitable supply 
of gluconeogenic substrates. In contrast, the ability of glucagon plus glycerol to increase 
plasma glucose might be attributed to the fact that the glucagon-up-regulated 
gluconeogenesis was able to recruit the G-3-P derived from glycerol to provide the needed 
carbon atoms for glucose synthesis.  
The glycerol treatment did not acutely affect plasma glucose in this study, which is 
consistent with other results (DeFrain et al., 2004). The increase in plasma glucose caused by 
glycerol in other studies (Goff and Horst, 2001) might be attributed to the use of larger (1 L) 
glycerol dosage. It was noticeable that plasma glucose responses increased with greater 
glycerol dosages (Goff and Horst. 2001) for longer time. 
On d 7 postpartum, both glucagon and glucagon plus glycerol treatments increased 
plasma glucose concentrations (Figure 2B). The ability of glucagon alone to increase plasma 
glucose concentrations on d 7 postpartum might be facilitated by the improved DMI, which 
provided more gluconeogenic substrates to fuel the gluconeogenesis. Similarly, on d 13 
postpartum, glucagon and glucagon plus glycerol treatments increased plasma glucose 
(Figure 2C) to be higher than that of the control. The increase in concentrations of plasma 
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glucose caused by glucagon observed in this study is consistent with that of She et al 
(1999a), Hippen et al., (1999a) Bobe et al (2003b), and Nafikov et al (2006). 
It seems reasonable to speculate that when glycerol is administered alone or in amount 
less than 1 L it is mostly converted to 1, 3 bisphosphoglycerate (1, 3-BPG) that supplies ATP 
and pyruvate in glycolysis. Increased availability of ATP would alleviate the need for more 
glucose synthesis and spare glucose for lactose synthesis. Consistent with this concept is the 
decrease in plasma glucagon concentrations caused by glycerol in a companion study 
(Osman et al., unpublished data). When co-administered with glucagon (this study) or in a 
larger amount (Goff and Horst, 2001), glycerol probably is converted to fructose 1, 6 
bisphosphate (F-1, 6-P2) that then supplies glucose by way of gluconeogenesis (Figures 2A, 
2B, and 8).    
The increase in postpartal plasma insulin concentrations caused by the glucagon plus 
glycerol treatment on d 1, d 7, and d 13 postpartum is consistent with the concurrent increase 
in plasma glucose concentrations caused by the same treatments. That glucagon treatment did 
not affect plasma insulin concentration during d 1 postpartum can be attributed to its lack of 
affect on plasma glucose concentration on the same day. Similarly, the glycerol treatment did 
not increase plasma insulin concentrations during the postpartal period because it did not 
increase plasma glucose concentrations (Figures 2A, 2 B, and 3 B). Thus, our data support 
the fact that glucagon indirectly increases plasma insulin concentrations by increasing plasma 
glucose via signals through the GBs class glucagon receptor (Jiang and Zhang, 2003). 
Furthermore, the signaling of glucagon through Gq class glucagon receptor to directly 
increase plasma insulin concentrations (Gromada et al., 1998) is probably only effective 
when plasma glucose is increased simultaneously. 
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On d 7 postpartum, both glucagon and glucagon plus glycerol treatments increased 
plasma insulin concentrations by 27.4 and 33.1 XU/mL, respectively (Figure 3C), which is 
significantly higher than that of the control. The increase of plasma insulin concentrations 
caused by glucagon on d 7 and d 13 postpartum (Figure 3B) is consistent with previous 
results (She et al., 1999b; Hippen et al., 1999a; Bobe et al., 2003a) and might be attributed to 
the concurrent increase in plasma glucose caused by glucagon treatment (Figures 2 B and 2 
C).  
Glucagon administration significantly decreased plasma NEFA concentrations (Figure 
4B), which lends support to other results (Hippen et al., 1999a; Bobe et al., 2003a). Oral 
administration of glycerol decreased plasma NEFA concentrations (Figures 4A, 4B, and 4C), 
which is also in congruence with results of other studies (Bodarski et al., 2006). Because 
glycerol did not increase plasma glucose and insulin concentrations, the mechanism whereby 
glycerol decreases plasma NEFA concentrations is possibly through increasing its 
esterification into TAG. Furthermore, glycerol can be absorbed through the ruminal wall and 
phosphorylated in the liver by glycerol kinase to B-glycerolphosphate (4-GP). Liver might 
use B-GP to esterify NEFA into TAG before it is exported to extrahepatic tissues (Figures 
6A, B, and C). Therefore, availability of B-GP probably enhances liver to take up more 
NEFA from blood, resulting in decreasing plasma NEFA concentrations.  
We are tempted to speculate that probably one purpose of the accelerated peripartal 
lipolysis is to supply glycerol that can be converted in the liver to G-3-P and utilized by 
gluconeogenesis to synthesize glucose to support milk lactose or used in glycolysis to 
directly produce the needed energy in the form of ATP plus pyruvate. In addition, because 
the G-3-P enters gluconeogenesis after the reactions catalyzed by the rate-limiting enzymes 
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pyruvate carboxylase (PC) and phosphoenolpyruvate carboxykinase (PEPCK) (Goff and 
Horst, 2001), glycerol can be used more efficiently than most other gluconeogenic substrates. 
Moreover, the surprising overwhelming of the liver by NEFA during the peripartal period 
could be explained by the fact that for each demanded molecule of glycerol, the liver has to 
cope with other 3 molecules of excess NEFA. It is possible, therefore, that, because of the 
short supply of B-GP that is needed to esterifye NEFA into TAG, NEFA might accumulate in 
liver. It could be speculated further that because of the negatively charged carbonyl tail, in 
contrast to TAG, accumulated NEFA might disturb the charge balance in the hepatocytes, 
which could play an active role in the pathogenesis of FLD.  
Glucagon plus glycerol decreased plasma NEFA concentrations (Figures 4B and 4C) 
probably through increasing the postpartal plasma glucose and insulin concentrations. 
Whereas increased plasma glucose improves the energy status of the cow and lessens the 
need for more lipolysis, increased plasma insulin is an anabolic and increases uptake and 
esterification of NEFA by the adipose tissues (Brockman et al., 1975).  
In general, plasma BHBA concentrations increased in all treatment groups during wk 1 
and decreased during wk 2 postpartum in accordance with the decrease of plasma NEFA 
concentrations. Glucagon, however, did not affect plasma BHBA concentrations on d 1, d 7, 
and d 13 postpartum. The lack of effects of glucagon on plasma BHBA is consistent with 
other results (She et al., 1999b; Hippen et al., 1999a; Bobe et al., 2003a). Glycerol 
administration decreased plasma BHBA concentrations during the postpartal period, which 
agrees with results of DeFrain et al (2004) who fed 430 g/d of glycerol. Additionally, Goff 
and Horst (2001) drenched dairy cows with glycerol and observed a decrease in urine ketones 
and symptoms of ketosis complicated with FLD. It is possible that glycerol decreased plasma 
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BHBA concentrations postpartum by increasing NEFA esterification and accordingly the 
disposal of NEFA from the liver as TAG. It is evident that glycerol is fermented in the rumen 
to propionate, acetate, and butyrate (Remond et al., 1993). Furthermore, the omasal and 
ruminal epithelium convert butyrate to BHBA to provide energy and lessen the toxicity of 
butyrate to digestive mucosa (Schröder and Südekum, 1999). Thus, feeding glycerol at 500 
g/d (Bodarski et al., 2006) or higher (DeFrain et al., 2004) might increase plasma BHBA. 
Because the origin of the increased plasma BHBA when feeding high amount of glycerol is 
not the result of down-regulated TCA cycle, probably increased plasma BHBA 
concentrations from feeding glycerol is not related to ketosis development. Furthermore, 
glucagon plus glycerol decreased postpartal plasma BHBA concentrations (Figures 5A, and 
5B) possibly because this treatment substantially decreased plasma NEFA (Figures 4A, 4B, 
and 4C), the precursor of BHBA 
Though direct stimulation of the net uptake of amino acids by liver (Brockman et al., 
1975) and increase of protein degradation (Kimball et al., 2004) are attributes of glucagon, 
glucagon and glucagon plus glycerol treatments did not increase postpartal PUN 
concentrations in our study (Figures 7A, 7B, and 7C). Furthermore, glucagon plus glycerol 
treatment did not affect PUN (Figures 7A, 7B, and 7C) possibly because the glucagon-
stimulated gluconeogenesis recruited the glycerol component as a glucogenic precursor and 
spared the use of glucogenic amino acids. 
Glucagon administration did not affect plasma TAG concentrations (Figures 6A, 6B, and 
6C); however, glycerol and glucagon plus glycerol treatments numerically increased plasma 
TAG concentrations in the first 3 h posttreatment (Figures 6A, 6B, and 6C). It is possible that 
the glycerol, after it was converted to B-GP, increased NEFA disposal from the liver in the 
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form of TAG. The Pearson’s coefficient for the correlation between plasma NEFA and TAG 
concentrations was small (-0.28) in the cows treated with the glucagon plus glycerol 
treatment. Nonetheless, the correlation suggests that glycerol probably facilitated the removal 
of liver NEFA in the form of TAG-VLDL. Furthermore, the increase in plasma TAG 
concentration immediately after the administration of the glycerol and the glucagon plus 
glycerol indicates possible shortages in B-GP availability in the liver. Limited availability of 
B-GP might cause NEFA to overwhelm the liver inducing FLD disease. This possible 
concept is supported further by the significant positive Pearson’s coefficient (0.71 to 0.78) 
for the correlation between plasma NEFA and TAG concentration observed in  cows treated 
with the glucagon treatment alone on d 1 and d 7 postpartum, respectively.   
CONCLUSION 
The results of this study suggest that glucagon and glycerol, when co-administered during 
early lactation, might act additively to increase plasma glucose and insulin concentrations 
and decrease plasma NEFA and BHBA concentrations. Therefore, co-administration of 
glucagon and glycerol seems to have greater potential to treat FLD and subsequently 
prevents other energy status-related peripartal metabolic and infectious health disorders than 
either glycerol or glucagon alone.  
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CHAPTER 3. CHRONIC METABOLIC RESPONSES OF TRANSITION 
DAIRY COWS WITH FATTY LIVER DISEASE TO SUBCUTANEOUS 
GLUCAGON INJECTIONS, ORAL GLYCEROL, OR BOTH 
 
A paper to be submitted to the Journal of Dairy Science 
 
M. A. Osman, N. A Mehyar, P. S. Allen, G. Bobe, J. F. Coetzee, K. Koehler, and D. C. Beitz 
ABSTRACT 
We examined the chronic effects of daily subcutaneous injections of 15 mg of glucagon 
with or without co-administration of 400 mL of glycerol orally on blood metabolites and 
hormones and liver composition of Holstein dairy cows during early lactation. Twenty 
multiparous cows of body condition score of P 3.5 points (1-5 point scale) were assigned 
randomly to one of four treatment groups--saline, glucagon, glycerol, or glucagon plus 
glycerol. Fatty liver was induced by feeding cows a dry-cow ration supplemented with 6 kg 
of cracked corn daily during the last six weeks of the dry period. Chronic administration of 
glucagon treatment increased (P = 0.04 and P =0.02) plasma glucose concentrations on d 9 
and d 13 postpartum, respectively, decreased (P = 0.05, P = 0.03, and P = 0.02) plasma 
nonesterified fatty acids (NEFA) concentrations on d 11, d 13, and d 15 postpartum, 
respectively, and increased (P = 0.0009 and P = 0.0045; Figure 2A) plasma J-
hydroxybutyrate (BHBA) concentrations on d 1 and d 5 postpartum, respectively. On the 
other hand, neither plasma triacylglycerol (TAG) nor plasma urea N (PUN) concentrations 
were altered (P P 0.76 and P P 0.25) by glucagon. Furthermore, glucagon plus glycerol 
treatment increased ( P O 0.05) plasma glucose concentrations on d 3 through d 13 
postpartum and insulin (P = 0.02) on d 11 postpartum, decreased plasma NEFA on d 5 
through d 15 postpartum (P O 0.05), and did not affect (P P 0.31, P  0.17, and P P 0.15 )
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plasma BHBA, TAG, and PUN, respectively. Additionally, glucagon plus glycerol treatment 
did not decrease (P = 0.8) liver glycogen content during the postpartal period. Interestingly, 
chronic administration of glycerol treatment decreased (P O 0.05) plasma glucagon 
concentrations on d 5 through d 15 postpartum and did not affect (P > 0.05) other plasma 
metabolites and hormones and liver composition. 
Chronic treatment of dairy cows during early lactation with glucagon plus glycerol for  
14 d increased plasma glucose and insulin, concurrently decreased plasma NEFA 
concentrations, and maintained liver glycogen content. Because the glucagon plus glycerol 
treatment was more efficacious than each of the glucagon or glycerol treatments alone in 
treating symptoms of FLD, we conclude that a single daily dose of glycerol for 14 days 
postpartum would chronically potentiate the action of glucagon to treat FLD in postpartal 
Holstein dairy cows.   
INTRODUCTION 
Early studies have shown that glucagon has the potential to prevent (Hippen et al., 1999a; 
Nafikov et al., 2006) and treat (Bobe et al., 2003c) experimental FLD in Holstein dairy cows 
during the postpartal period. Glucagon alleviates symptoms of FLD by increasing plasma 
glucose and insulin and by decreasing plasma NEFA concentrations (She et al., 1999a; 
Hippen et al., 1999ab; Bobe et al 2003c; Nafikov et al., 2006). Glucagon increases plasma 
glucose by up-regulating gluconeogenesis in liver by increasing gene expression of 
phosphoenolpyruvate carboxykinase (PEPCK) (Beale et al., 1984). Additionally, glucagon 
up-regulates gluconeogenesis and down-regulates glycolysis by regulating the bifunctional 
enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/F-2,6-BPase) (Okar 
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et al., 2004) and gene expression of pyruvate kinase (PK) (Pilkis and Claus, 1991). However, 
the spontaneous decline of dry matter intake (DMI) to about 70 % of normal intake by dairy 
cow might limit the availability of the gluconeogenic precursors (Doepel et al., 2002; Bertics 
et al., 1992; Hayirli et al., 2002b). The simultaneous increase in the energy requirement for 
fetus and milk production during the peripartal period causes the dairy cow to develop 
negative energy balance (NEB). However, the use of the gluconeogenic precursors such as 
propylene glycol, propionate salts, and amino acids to accelerate the gluconeogenesis and 
ameliorate the NEB was not as successful (Hoedemaker et al., 2004; Juchem et al., 2004; 
Goff et al., 1996; Greenfield et al., 2000). The limited availability of gluconeogenic 
precursors because of the decreased DMI might impede the ability of exogenous glucagon to 
increase plasma glucose production by gluconeogenesis.  
Glycerol is metabolized in the rumen and liver to intermediates of gluconeogenesis and 
glycolysis (Remond et al., 1993; Goff and Horst, 2001) with potential to alleviate the 
peripartal NEB encountered by dairy cows. Furthermore, glycerol could be converted in the 
liver to B-glycerol phosphate (4-GP) and used to esterify excess NEFA into TAG that can be 
exported as VLDL. Alternatively, B-GP could be converted to glyceraldehyde-3-phosphate 
(G-3-P) and used in gluconeogenesis to produce glucose or in glycolysis to produce energy 
in the form of adenosine triphosphate (ATP) and pyruvate. Recently, we have shown that 
glucagon and glycerol act additively to alleviate FLD in dairy cows when co-administered 
during postpartal period (Osman et al., unpublished data). We further elucidated the 
underlying acute biochemical mechanisms whereby glycerol potentiates the biochemical 
action of glucagon. We hypothesized that the biochemical effect of glucagon when injected 
at 15 mg/d could be sustained longer by co-administering of a single daily dose of 400 mL/d 
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oral glycerol. The objective of this study was to elucidate the chronic effects of glucagon and 
glycerol on plasma metabolites and hormones and liver composition of Holstein dairy cows 
induced with FLD.  
MATERIALS AND METHODS 
Experimental Design 
To test the hypothesis that 400 mL/d of oral glycerol could sustain the action of 15 mg/d 
of glucagon injection to treat FLD, we selected 20 multiparous Holstein dairy cows of BCS P
3.5 during the dry period. Selected cows were assigned at random to receive saline (control), 
glucagon, glycerol, or glucagon plus glycerol treatments. Experimental cows were housed in 
straw-bedded free stall. To induce postpartal FLD development, dairy cows fed ad libitum a
TMR dry-cow ration supplemented with six kg of cracked corn during the last six wk of the 
dry period (Bobe et al., 2003c). Additionally, cows were offered grass hay ad libitum. Once 
on the experiment, all cows were monitored closely for fatty liver-related peripartal health 
disorders under veterinary supervision. Following parturition, experimental cows were 
housed in a sand-bedded tie stall and offered NRC (2001) recommended TMR for high 
producing dairy cows twice a day at 0900 and 1500 h. Furthermore, treatment administration 
was commenced on d 0 postpartum as described elsewhere (Osman et al., unpublished data). 
Briefly,  4 h after parturition, control group cows (n = 4) received 60 mL of 0.9 % sodium 
chloride under the skin of the neck each 8 h daily for 14 d. Glucagon group cows (n = 4) 
received 5 mg of glucagon (donated by Eli Lilly and Co., Indianapolis) dissolved in 60 mL of 
0.9 % sodium chloride and injected under the skin of the neck each 8 h for 13 d, 16 h apart 
on d 14, and a single injection on d 15 postpartum. Glycerol group cows (n = 6) received 
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orally 400 mL of pure glycerol (West Central Inc., Ralston, IA) diluted with 100 mL of water 
once a day at 6:00 AM for 14 d. Glucagon plus glycerol group cows (n = 6) received both 
treatments as described above. Glucagon solutions were prepared in glassware that was pre-
rinsed with 1 % BSA (cat. number A8327, Sigma, St. Louis, MO, USA) in 0.9 % sodium 
chloride. Additionally, the glassware for storing glucagon and sodium chloride solutions 
were autoclaved. To ensure sterility of solutions, a bacterial filter was used to add solutions 
to the bottles. Furthermore, the ready-to-inject glucagon and sodium chloride solutions (pH = 
10.25) were stored at 4 0C for no longer than 36 h. All the experimental and surgical 
procedures used in this study were approved by the Iowa State University Committee on 
Animal Care. 
Sampling and Analysis 
Blood. To monitor the chronic effect of treatments, a single blood sample was collected 
every other day from the coccygeal artery from d -7 to d 15 relative to parturition one hour 
after treatment administration.  Twenty milliliters of blood were collected into two 
Vacautainer® tubes (Tyco Health Care Group LP, Mansfield, MA) containing Na2-EDTA and 
placed on ice until plasma was separated by centrifugation at 500 x g for 20 min at 4°C. 
Harvested plasma was stored at – 20°C until analyzed for concentrations of glucose (kit 
number G7519-500, Pointe Scientific Inc., Canton, MI), NEFA (NEFA C kit number 994-
75409, Wako, Richmond, VA), BHBA (kit number H7587-58, Pointe Scientific Inc., Canton, 
MI), PUN (kit number B7551-120, Pointe Scientific Inc., Canton, MI), glycerol (kit number 
F 6428, Sigma, Saint Louis, MI), and TAG (kit number T7532-120, Pointe Scientific Inc, 
Canton, MI) adapted for the mircoplate reader (SPECTRA Max PLUS, Sunnyvale, CA). For 
plasma hormone determination, 1 mL of plasma was mixed with 500 KIU of apoprotinin 
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(Boehringer-Mannheim, Indianapolis, IN) and analyzed for plasma glucagon and insulin 
concentrations (kit number GL-32K and PI-12K, Linco Research Inc., St. Louis, MO).  
Liver Tissue. Liver tissue samples were collected by puncture biopsy (Bobe et al., 2003c) 
on d -4 and d 9 relative to parturition. Local anesthesia (2% lidocaine hydrochloride) was 
used to ensure comfort of the animals. Furthermore, an ultrasound system (Aloka Micrus 
500, Corometrics Inc., Wallingford, CT) was used to guide the biopsy needle into the liver 
tissues. Liver tissue samples were rinsed with an ice cold 0.9 % sodium chloride, blotted free 
of moisture and frozen in liquid nitrogen for storage at -80°C. Liver tissue samples were 
analyzed for total lipids (Ametaj et al., 2003), glycogen (Bobe et al., 2003c), and TAG 
(Hippen et al., 1999b).  
BCS and Fatty Liver-Related Health Disorders.  BCSs of all cows were measured on d -
47, d -7, d 1, d 7, and d 14 relative to parturition. To monitor incidence of fatty liver-related 
health disorders, a comprehensive veterinary physical examination was conducted daily at 
6:00 AM in the flat barn. Urine ketone bodies, rectal temperature, and heart and respiratory 
rates were monitored daily. Signs of retained placenta, mastitis, dysentery, and lameness 
were observed closely.  Furthermore, for detection of displacement of the abomasum, 
auscultation and percussion technique was adopted on all cows. 
Milk Production. The daily milk production in kg was recorded for the morning and 
evening milkings and composited for the day.  
Statistical Analysis 
Data were expressed as the means ± standard error of the means. The statistical analyses 
were done by using the MEANS and GLM procedures of SAS (SAS Institute Inc., Cary, NC, 
USA), version 9.1 (SAS, 2002). For the statistical analyses of plasma metabolites and 
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hormones, the MEANS procedure was used to compute the prepartal and postpartal means of 
each response variable (plasma glucagon, glucose, insulin, NEFA, BHBA, PUN, and TAG) 
on the period d -7 through d 15 relative to parturition for each cow in each treatment group. 
The differences in means were analyzed by using the GLM procedure to evaluate the effects 
of treatments. By using the Fisher’s criterion, differences among treatments were only 
analyzed if the F-test of testing the null hypothesis of no treatment effects was significant at 
the 0.05 level of significance. Whenever a significant F-test was obtained, glucagon, 
glycerol, and glucagon plus glycerol treatments were compared to the control treatment using 
the t-test. Two treatments were declared significantly different if the corresponding t-test was 
significant at the 0.05 level. Liver composition data were analyzed by using the MIXED 
procedure of SAS. The model statement included effect of treatment, time, and interaction of 
treatment with time. Furthermore, the denominator degrees of freedom were approximated 
using the Satterthwaite formula. The daily milk production was analyzed by fitting a linear 
mixed model that assumes a random cow effect. For the measurement within each cow, we 
used a first-order autoregressive covariance structure that assumes that the adjacent 
observations tend to be more correlated than observation farther apart in time. Therefore, the 
MIXED procedure of SAS was used with a model statement included treatment , day, 
treatment by day interaction. Furthermore, Satterthwaite formula for approximation of the 
denominator degrees of freedom was used. Differences were considered significant if the 
corresponding t-test was significant at the 0.05 level. 
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RESULTS 
Plasma Constituents 
Plasma Glucagon. We verified the effectiveness of exogenous glucagon administration 
on plasma glucagon concentrations. Overall, chronic administration of glucagon and 
glucagon plus glycerol during the first 2 wk postpartum significantly increased (P < 0.0001
and P < 0.0001; Figure 1A) plasma glucagon concentrations. Chronic administration of 
glycerol treatment, however, decreased (P O 0.05; Figure 1A) plasma glucagon 
concentrations on d 5 through d 15 postpartum. 
Plasma Insulin. Chronic glucagon plus glycerol administration numerically increased 
plasma insulin concentration starting at d 0 postpartum (Figure 1B). However, the increase in 
plasma insulin became significant (P = 0.02; Figure 1B) on d 11 postpartum. On the other 
hand, administration of glucagon caused a numerical increase in plasma insulin starting at d 5 
postpartum. Furthermore, glucagon numerically increased plasma insulin concentration 
starting on d 5 postpartum. Despite this, neither the effect of glucagon nor the effect glycerol 
significantly altered (P P 0.17 and P P 0.65, respectively; Figure 1B) plasma insulin 
concentrations. 
Plasma Glucose. The chronic administration of glucagon increased plasma glucose 
concentration starting on d 7 postpartum. But the significant increase (P = 0.04 and P =0.02; 
Figure 2A) of plasma glucose concentrations was, however, observed on d 9 and d 13 
postpartum, respectively. Similarly, the glucagon plus glycerol treatment increased (P O 0.05;
Figure 2A) plasma glucose concentrations on d 3 through d 13 postpartum. On the other 
hand, the glycerol treatment did not change (P P 0.29; Figure 2A) plasma glucose 
concentrations chronically during the postpartal period. 
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Figure 1. Plasma hormone concentrations of cows treated with saline, glucagon, 
glycerol, or glucagon plus glycerol. Panel A, plasma glucagon concentration. Glycerol 
effects differed (P H 0.04; SEM = 29.3) on d 5, d 7, d 9, and d 11 postpartum. Glucagon 
effects significantly differed (P H 0.008; SEM = 29.3 to 59.6) on d 1, d 3, d 5, d 7, d 9, d 
11, d 13 and d 15 postpartum. Glucagon plus glycerol effects highly significantly 
differed (P H 0.0001; SEM = 29.3 to 59.6) on d 1, d 3, d 5, d 7, d 9, d 11, d 13, and d 15 
postpartum. Panel B, plasma insulin concentrations. Glucagon and glycerol effects were 
not different (P G 0.17 and P G 0.65, respectively; SEM = 2.5 to 8.5). Glucagon plus 
glycerol effects, however, were different (P = 0.02; SEM = 4.8 to 5.5) on d 11 and tended 
to be different (P = 0.07 and P = 0.07; SEM = 7.3 to 7.4) on d 7 and d 9 postpartum, 
respectively.  
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Plasma NEFA. Plasma NEFA concentration was decreased (P = 0.05, P = 0.03, and P =
0.02; Figure 2B) by glucagon on d 11, d 13, and d 15 postpartum, respectively. Similarly, 
glucagon plus glycerol caused plasma NEFA concentrations to decrease (P = 0.03, P = 0.03,
P = 0.02, P = 0.05, and P = 0.006; Figure 2B) on d 5, d 7, d 11, d 13, and d 15 postpartum, 
respectively. Also, chronic treatment with glycerol tended to decrease (P = 0.09; Figure 2B) 
plasma NEFA concentrations on d 15 postpartum. 
Plasma BHBA. The chronic administration of glycerol and glucagon plus glycerol did 
not change (P = 0.14 and P = 0.10; Figure 2C) plasma BHBA concentrations. Conversely, 
chronic glucagon administration significantly increased (P = 0.009 and P = 0.0045; Figure 
2C) plasma BHBA concentration on d 1 and d 5 postpartum, respectively.   
Plasma TAG. Overall, chronic administration of glucagon and glycerol treatments 
triggered no change (P P 0.77 and P P 0.65, respectively; Figure 2D) in plasma TAG 
concentrations during the postpartal period. However, a tendency (P = 0.09; Figure 2D) for 
glucagon plus glycerol treatment to decrease plasma TAG concentration was observed on d 
13 postpartum. In general, plasma TAG concentration decreased in all treatment groups 
during d 1 and d 2 postpartum and remained relatively constant.  
BCS and Fatty Liver–Related Health Disorders. On d 7 prepartum, BCS averaged 3.41, 
3.83, 3.55, and 3.47 in the cows assigned to saline, glucagon, glycerol, and glucagon plus 
glycerol treatments, respectively (data not shown). By using the prepartal average BCS as a 
covariate, differences among BCSs were not significant (P P 0.21). Incidence of various 
peripartal health disorders did not differ among treatment groups (Table 1). The incidence of 
every fatty liver-related health disorder as percentage of all health disorders observed during 
the peripartal period  were ketosis at 33.3 %, milk fever at 26.7%, laminitis at 13.3 %, and  
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Figure 2. Plasma metabolites concentrations of cows treated with saline, glucagon, 
glycerol, or glucagon plus glycerol. Panel A, plasma glucose concentrations. Glucagon 
effects were different (P H 0.02; SEM = 7.7 to 9.0) on d 9 and d 13 postpartum. 
Glucagon plus glycerol effects were different (P H 0.05; SEM = 4.8 to 9.0) on d 3, d 5, d 
9, d 11, and d 13 postpartum. Glycerol effects, however, did not differe (P G 0.09; SEM 
= 4.8 to 9.7). Panel B, plasma NEFA concentrations. Glucagon effects were different (P
H 0.05; SEM = 0.08 to 0.18) on d 11, d 13, and d 15 postpartum. Similarly, glucagon plus 
glycerol effects were different (P H 0.03; SEM = 0.13 to 0.20) on d 5, d 7, and d 11 
postpartum, but glycerol effects were not different (P G 0.09; SEM = 0.07 to 0.18). Panel 
C, plasma BHBA concentrations. Glycerol and glucagon plus glycerol effects were not 
different (P G 0.10 and P G 0.31, respectively; SEM = 0.09 to 0.68), however, glucagon 
effects were different (P = 0.009 and P = 0.005; SEM = 0.11 to 0.28) on d 1 and d 5 
postpartum, respectively. Panel D, plasma TAG concentrations. Glucagon, glycerol, 
and glucagon plus glycerol effects did not differ (P G 0.77, P G 0.65, and P G 0.09,
respectively; SEM = 6.4 to 62.9). 
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retained fetal membranes, unspecified fever, dysentery, and LDA each at 6.7 % of total 
health disorders (Table 1).  
Milk Production. Effect of day in milk (DIM) on milk production was detected (P =
0.04). Effects of treatment and the interaction of day and treatment were not apparent (P =
0.29 and P = 0.58, respectively).  Overall, administration of glucagon, glycerol, and glucagon 
plus glycerol treatments did not affect (P = 0.14, P = 0.73, and P = 0.81, respectively, Figure 
4) the daily milk production.  
Liver Composition 
Liver Total Lipids. Around d 4 prepartum, liver total lipids content averaged 4.3 % (wet 
wt %) in all treatment groups and increased significantly (P = 0.0001, P = 0.0001, P =
0.0001, and P = 0.0002, respectively, Figure 5A) in the saline-, glucagon-, glycerol-, and 
glucagon plus glycerol-treated cows. Overall, effects of treatment and the interaction of 
treatment × time were not significant (P = 0.84 and P = 0.39, respectively). In contrast, effect 
of time on liver total lipids content was highly significant (P = 0.0001). In comparison with 
the control group, administration of glucagon, glycerol, and glucagon plus glycerol 
treatments did not significantly (P = 0.90, P = 0.34, and P = 0.29, respectively) affect liver 
total lipids on d 9 postpartum.  
Liver TAG. Liver TAG contents significantly increased (P = 0.006, P = 0.0004, and P =
0.004, and P = 0.008; Figure 5B) on d 9 postpartum in the saline-, glucagon-,glycerol-, and 
glucagon plus glycerol-treated cows, respectively, relative to that of d 4 prepartum. When 
contrasted to that of the control cows, however, glucagon, glycerol, and glucagon plus 
glycerol treatments did not significantly alter (P = 0.90, P = 0.34, and P = 0.29; Figure 5B) 
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Table 1. Incidence of fatty liver-related peripartal health disorders of cows treated with 
saline, glucagon, glycerol, or glucagon plus glycerol during the first 14 days of the 
postpartal period. 
 
Treatment/ 
Disorder Ketosis LDA RP Laminitis Fever MF Dysentery Total 
Saline 1 -- 1 1 -- -- -- 3 
Glucagon 2 -- -- 1 -- 1 -- 4 
Glycerol 1 -- -- -- 1 1 -- 3 
Glucagon-
glycerol 
1 1 -- -- -- 2 1 5 
Abbreviation: LDA, left displacement of the abomasum; RP, retained placenta; and 
MF, milk fever. 
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Figure 3. Body condition scores of cows treated with saline, glucagon, glycerol, or 
glucagon plus glycerol. Differences in BCS were not significant (P G 0.21) during the 
treatment period 
 
78
0 2 4 6 8 10 12 14 16
15
20
25
30
35
40
45
50
M
i l k
p r
o d
u c
t i o
n ,
k g
Time relative to parturition, d
Saline
Glucagon
Glycerol
GlucGlyc
 
Figure 4. Milk production of cows treated with saline, glucagon, glycerol, or glucagon 
plus glycerol. Effects of glucagon, glycerol, and glucagon plus glycerol treatments were 
not different (P G 0.14; SEM = 4.8 to 5.1). 
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Figure 5. Liver composition on d 9 postpartum of cows treated with saline, glucagon, 
glycerol, or glucagon plus glycerol. Panel A., liver total lipids percentage (wet wt). 
Effects of glucagon, glycerol, and glucagon plus glycerol were not significant (P = 0.90,
P = 0.34, and P = 0.29, respectively; SEM = 2.20 to 2.32). Panel B, liver TAG percentage 
(wet wt). Effects of glucagon, glycerol, and glucagon plus glycerol were not different (P
= 0.90, P = 34, and P = 0.29, respectively; SEM = 2.27 to 2.39). Panel C, liver glycogen 
percentage (wet wt) glucagon, glycerol, and glucagon plus glycerol effect did not differ 
(P = 0.58, P = 0.28, and P = 0.28, respectively; SEM = 0.38 to 0.41). Panel D, liver TAG 
to glycogen ratio. Effects of glucagn, glycerol, and glucagon plus glycerol were not 
different (P = 0.39, P = 0.44, and P = 0.40, respectively; SEM = 8.4 to 8.7).   
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liver TAG on d 9 postpartum. Again, the TAG contents of the glycerol- and glucagon plus 
glycerol-treated cows were decreased numerically (Figure 5B). On the whole, whereas effect 
of time was significant (P = 0.0001) on liver TAG content (wet wt), effects of treatment and 
the interaction of time × treatment were not significant (P = 0.50 and P = 0.39, respectively, 
Figure 5B).  
Liver Glycogen. Relative to that of d 4 prepartum, significant decrease (P = 0.0001;
Figure 5C) of glycogen content (wet wt %) on d 9 postpartum was detected in livers of cows 
treated with glucagon, glycerol, and glucagon plus glycerol treatments. Relative to that of the 
control cows, glucagon, glycerol, and glucagon plus glycerol administration, however, did 
not alter (P = 0.58, P = 0.28, and P = 0.28, respectively; Figure 5C) liver glycogen content 
relative to that of the control cows. Generally, time effect was significant (P = 0.0001) and 
the interaction of time × treatment tended to be significant (P = 0.06). But treatment effect 
was not significant (P = 0.27). 
Ratio of Liver TAG to Glycogen. Compared with that of d 4 prepartum, ratio of TAG to 
glycogen did not increase (P = 0.58 and P = 0.71, respectively) in livers of cows treated with 
glycerol and glucagon plus glycerol on d 9 postpartum. On the other hand, glucagon 
treatment increased (P = 0.018) liver TAG to glycogen ratio on d 9 postpartum (Figure 5D). 
Relative to that of the control, glucagon, glycerol, and glucagon plus glycerol administration 
did not vary (P = 0.39, P = 0.44, and P = 0.40, respectively) TAG to glycogen ratio. Overall, 
TAG to glycogen ratio was effected by time (P = 0.03), but not by treatment and the 
interaction of treatment × time (P = 0.30 and P = 0.31, respectively, Figure 5D). 
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DISCUSSION 
We have previously shown that glucagon and glycerol act additively when co-
administered to acutely improve indicators of energy status in postpartal Holstein dairy cows 
(Osman et al., unpublished data). We further demonstrated that the additiveness of 
biochemical effects of glucagon and glycerol was not affected by DIM by measuring their 
acute effects on blood metabolites and hormones on d 1, d 7, and d 13 postpartum (Osman et 
al., unpublished data). The main objective of the current study was to examine the chronic 
effects of the subcutaneous injection of 15 mg of glucagon with or without 400 mL of oral 
glycerol per day on blood metabolites and hormones, liver composition, and performance of 
Holstein dairy cows during the early lactation. 
Administration of glucagon and glucagon plus glycerol treatments increased plasma 
glucagon concentration about seven-fold regardless of the DIM (Figure 1A). Similar results 
were reported earlier by our laboratory (Hippen et al., 1999b; She et al., 1999ab) and 
indicated that the methods of glucagon preparation and administration were effective. 
Unexplainably, glycerol treatment decreased postpartal plasma glucagon concentration 
relative to that of the control group (Figure 1A). 
Plasma insulin concentrations, though numerically increased, did not significantly change 
because of glucagon administration (Figure 1B), which is in congruence with previous results 
(Hippen et al., 1999b). Earlier studies (Nafikov et al., 2006; Bobe et al., 2003c), however, 
reported an increase of insulin caused by glucagon administration. Differences among our 
results and those of Nafikov et al (2006) and Bobe et al (2003c) might by attributed to the 
inadequate cow numbers and higher BCS (data not shown) of the glucagon cows used in our 
study. It has been reported that cows that calve at higher BCS have lower plasma insulin 
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concentrations than do cows that calve with a lower BCS (Pedron et al., 1993). Probably the 
low plasma insulin concentration observed in these cows allow for more lipid mobilization 
during early lactation (Pedron et a., 1993). In contrast, glucagon plus glycerol significantly 
increased plasma insulin concentration (Figure 1B), which mimics its potent action on 
plasma glucose concentration. Consistent with the results of DeFrain et al (2004), glycerol 
treatment did not affect plasma insulin concentration (Figure 1B).   
Postpartal plasma glucose concentration was raised by the glucagon treatment on d 9 and  
d 13 postpartum (Figure 2A). This result confirms previous findings in our research group 
(She et al., 1999ab; Hippen et al., 1999b; Bobe et al., 2003c; Nafikov et al., 2006). Glucagon 
signaling is known to potentiate gluconeogenesis and glycogenolysis by activating a cAMP 
cascade. Concurrently, glucagon inhibits glycolysis and glycogenesis by regulating the 
concentration of fructose 2, 6 bisphosphate and activity of pyruvate kinase (Hue, 1982; Hue 
and Bartrons, 1983). Consequently, hepatic output of glucose increases. The effect of 
glucagon on glycolysis and gluconeogenesis is, however, substrate-mediated. When the 
gluconeogenic substrates such as the alanine and lactate that enters gluconeogenesis pathway 
at the pyruvate level, glucagon inactivates the pyruvate kinase, which inhibits glycolysis. 
Whereas when the dihydroxyacetone phosphate (DHAP) being the gluconeogenic substrate 
entering the gluconeogenesis at the triose phosphate level, glucagon increases activity of the 
fructose-2, 6-bisphosphatase (Hue and Bartrons, 1983) and thus stimulates gluconeogenesis 
and inhibits glycolysis.  
The glucagon plus glycerol treatment significantly increased plasma glucose 
concentration (Figure 1B). According to previous research (Hue and Bartrons, 1983), 
glucagon does not increase glucose production from glycerol in hepatocyte cultures. In 
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contrast, glucagon increased the net glucose production from DHAP. It could be argued that 
because Hue and Bartrons (1983) used hepatocytes that were derived from overnight starved 
rats, probably adequate ATP to phosphorylate glycerol to glycerol-3-phosphate, prior to its 
utilization by gluconeogenesis, was not available. In support of this contention, glycerol 
infusion did not increase plasma glucose concentration in fasted humans (Jahoor et al., 1990).  
That glycerol treatment at 400 mL per day did not increase plasma glucose concentration 
of early lactation dairy cows is consistent with other results (Bodarski et al., 2006; DeFrain et 
al., 2004). Larger doses of glycerol (1, 2, and 3 L), however, increased plasma glucose 
concentration by 16 to 25 % over pretreatment value for more than 8 hours (Goff and Horst, 
2001). The decrease of plasma glucagon caused by glycerol in this study (Figure 1A) might 
be a significant proof of an improved energy status of the cows. It is possible that the 
glycerol is a preferred glycolytic substrate, and, when glycolysis need of precursors is met or 
alternatively glycolysis is inhibited (e.g., by glucagon), glycerol is partitioned to 
gluconeogenesis for glucose production. Overall, glycerol contributes about 4 % and alanine 
contributes about 8 % of net hepatic glucose synthesis during transition and early lactation 
periods (Reynolds et al., 2003). But, because glycerol could be converted to pyruvate and 
alanine, maybe glycerol contributes more glucose than was previously thought.   
In the present study and others (Hippen et al., 1999b; Bobe et al., 2003c; Nafikov et al., 
2006), glucagon caused plasma NEFA concentration to decline (Figure 2B). It is likely that 
the increase of plasma glucose concentration stimulated by glucagon had decreased the need 
for more lipolysis. Furthermore, the slight increase of plasma insulin concentration caused by 
glucagon (Figure 1B) might have decreased lipolysis via activating phosphodiesterase that 
hydrolyzes cAMP and thus inactivates protein kinase A and hormone-sensitive lipase 
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(Degerman et al., 1997). Additionally, insulin might have increased the reuptake and 
esterification of NEFA by adipose tissue (Brockman et al., 1975). Similarly, glucagon plus 
glycerol decreased plasma NEFA concentration more precipitously than did the glucagon or 
the glycerol treatment alone.  Probably, the glycerol component of the glucagon plus glycerol 
treatment augmented the action of glucagon by providing the B-GP backbone that accelerated 
hepatic uptake, esterification, and removal of NEFA as TAG. Previously, we have showed 
that, in cows treated with glucagon plus glycerol, plasma NEFA and TAG are correlated 
negatively and the Pearson’s correlation coefficient was (-0.28) (Osman et al., unpublished 
data). 
Plasma BHBA concentration did not respond to the glycerol and the glucagon plus 
glycerol treatments (Figure 2C). In agreement, DeFrain et al (2004) fed 430 and 860 g of 
glycerol daily to transition cows and observed no change in postpartal plasma BHBA 
concentrations. Because the fermentation of glycerol in the rumen produces propionate, 
acetate, and some butyrate, which tends to increase plasma BHBA concentration, the 
glucogenic value of the glycerol was questioned (Bodarski et al 2006; Remond et al., 1993; 
DeFrain et al., 2004). We propose that because the origin of the increased plasma BHBA is 
the ruminal fermentation of glycerol, and not the impaired tricarboxylic acid (TCA) cycle 
activity in the liver, when glycerol is fed, increased plasma BHBA concentrations might be 
unrelated to the pathogenesis of ketosis. Thus, the glucogenic capacity of the glycerol might 
be of value. 
The chronic administration of the glucagon treatment significantly increased plasma 
BHBA concentration during the first wk postpartum (Figure 2C). However, studies by She et 
al. (1999a), Bobe et al (2003c), and Nafikov et al. (2006) demonstrated no effect of glucagon 
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on plasma BHBA concentration. Furthermore, the increase of plasma BHBA concentration 
during wk 1 can be explained by the lack of effect of the glucagon treatment on plasma 
glucose, insulin, and NEFA concentrations during wk 1 (Figures 1B, 2A, and 2B). Possibly, 
because the glucagon-treated cows had the largest BCS during the peripartal period (Figure 
3), they experienced more lipolysis, which increased plasma BHBA (Figure 2C). Larger BCS 
at calving decreased plasma insulin concentration during early lactation probably to allow for 
increased adipose tissue mobilization to supply energy (Pedron et al., 1993). Despite the high 
total liver content in the glucagon-treated cows, the glucagon treatment numerically 
decreased plasma BHBA concentration (Figure 2A) during wk 2 postpartum, which closely 
follows its effects on plasma glucose, insulin, and NEFA during the same time (Figure 1B, 
1C, and 1D).  
Plasma TAG was not altered by chronic glycerol or glucagon treatments (Figure 2D). 
However, the tendency of the glucagon plus glycerol treatment to decrease plasma TAG 
could be attributed to the decreased plasma NEFA concentration caused by the same 
treatment (Figures 1D and 2B). Furthermore, plasma TAG steeply decreased on d 1 and d 2 
postpartum and became lower than the prepartal concentrations for all treatment groups 
(Figure 2D). Similar decrease of plasma TAG during early postpartal period was reported by 
Bobe et al (2003b). The decreased availability of B-GP in liver might have caused a 
simultaneous decrease in plasma TAG concentration. As the dairy cow proceeds through the 
transition period, metabolism of TAG, however, seldom changes (Reynolds et al., 2003).  
Even though cow numbers were relatively small, incidence of fatty liver-related 
peripartal health disorders as percentages of total postpartal health disorders indicated 
prevalence of ketosis at 33.3 % followed by milk fever at 26.7 % and laminitis at 13.3 % 
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(Table 1). The high incidence of ketosis in this study indicates the intimate relationship with 
FLD as a cause of ketosis (Bobe et al., 2003c; Goff, 2006). Results so far indicate that the 
inadequate DMI during the peripartal period limits calcium, selenium, and vitamin E intake, 
predisposing the dairy cow to milk fever and immune incompetence (Goff, 2006). Increased 
hepatic TAG because of FLD impaired both the humoral and cellular responses of affected 
dairy cows (Wentink et al., 1997) and decreased the cytotoxic functions of the polymorph 
neutriphils (PMN) in their blood and uteri (Zerbe et al., 2000). Impaired PMN functions 
predispose the dairy cows to develop mastitis, retained placenta, metritis, and other infectious 
diseases during the peripartal period. Similarly, increased postpartal plasma NEFA 
concentration P 0.5 mEq / L increased the incidence of retained placenta in dairy cows by 80 
% (LeBlanc et al., 2004). IL-8 in the cotyledons of the uterus serves as a chemo-attractant 
that direct the PMN to the cotyledons to initiate the detachment of the placenta. In dairy cows 
susceptible to retained placenta, IL-8 decreases impairing the chemotactic function of PMN 
(Kimura et al., 2002).  In addition, the inadequate DMI results in a decreased neutral 
detergent fiber intake, which limits chewing, salivation, and thus buffering of rumen. 
Consequently, ruminal acidosis and laminitis tend to develop (Goff, 2006). Furthermore, 
because fatty liver causes insulin resistance (Bobe et al., 2004) and thus raises plasma insulin 
concentration, hyperinsulinemia decreases the rate of abomasum emptying, which may 
induce LDA (Holtenius and Traven, 1990).   
Earlier studies (Bobe et al., 2003c; Nafikov et al., 2006) reported no effect of glucagon 
on milk production. Because glucagon injection does not decrease feed intake (Bobe et al., 
2003c), milk production does not decrease. However, in the present study, glucagon 
treatment numerically increased the daily milk production. Probably the increase of plasma 
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glucose and insulin caused by glucagon alleviated the NEB and allowed for milk production 
to increase. A previous study indicated that high BCS at calving was associated with 
increased milk production at early lactation (Pedron et al., 1993). Furthermore, drenching 
glycerol at 400 mL per day (this study) or feeding glycerol at 430 and 860 g per day (DeFrain 
et al., 2004) did not change the milk production (Figure 4). In contrast Goff and Horst (2001) 
observed an increase of milk production when 1 L or more of glycerol was drenched to dairy 
cows. 
Postpartal liver total lipids (wet wt %) did not change by glucagon treatment (Figure 5A). 
Previous studies (She et al., 1999b; Nafikov et al., 2006) did not detect glucagon effect on 
liver total lipids. Glucagon is known to increase lipolysis, ketogenesis, and insulin secretion. 
The increase in plasma insulin concentrations, however, decreases lipolysis and increases the 
esterification of NEFA into TAG (Hales et al., 1978). Furthermore, the insulin induces 
translocation of fatty acid transport proteins (FATPs) 1 and 4 from perinuclear compartment 
in adipocytes to plasma membrane. Consequently, the insulin increases NEFA uptake into 
adipocytes (Stahl et al., 2002). Similar to results of DeFrain et al (2004), glycerol did not 
alter liver total lipids content during postpartal period.  
On d 9 postpartum, TAG in livers of cows ranged from 8 to 14% (wet wt %) (Figure 5B). 
Furthermore, liver TAG were increased significantly compared with that on d 4 prepartum in 
all treatment groups. According to Bobe et al (2004), whereas the saline- and glucagon-
treated cows developed severe FLD (13 and 14% TAG, respectively), the glycerol- and the 
glucagon plus glycerol-treated cows developed moderate FLD (8.7 and 8.0% TAG, 
respectively). However, when the difference in the prepartal BCS was accounted for by using 
the covariance analysis, the glucagon- treated cow developed moderate FLD (7.8% TAG) 
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and the glycerol- and glucagon plus glycerol-treated cows developed mild FLD (5.2 and 
4.9% TAG, respectively).  
The postpartal numerical increase in liver glycogen (wet wt%) caused by glucagon plus 
glycerol could be explained by the ability of glucagon plus glycerol treatment to concurrently 
increase plasma glucose and insulin (Figures 2A, 2B, 2D, 3A, 3B, and 3D). In this study and 
others (Bobe et al., 2003c; Nafikov et al., 2006), subcutaneous glucagon injection did not 
alter postpartal liver glycogen (Figure 5C). However, intravenous infusion markedly depleted 
liver glycogen followed by replenishment (She et al., 1999a; Hippen et al., 1999b). Despite 
the chronic decrease of plasma glucagon caused by the glycerol treatment, glycerol treatment 
did not increase liver glycogen content. This observation might be explained by the possible 
ability of glycerol to directly supply ATP and pyruvate through glycolysis to improve the 
energy balance without increasing plasma glucose concentration (Figure 2D).  
An increase in liver TAG to glycogen ratio was suppressed by glycerol and glucagon plus 
glycerol treatments on d 9 postpartum. Ability of the glycerol to provide B-GP that facilitates 
removal of liver NEFA probably decreased liver TAG content. In contrast, the observed 
increase in liver TAG in the glucagon-treated cows provides another evidence of the role of 
glycerol in removal of liver TAG.  
CONCLUSION 
The data presented here point out several pieces of evidence that glycerol has the 
potential to enhance the chronic effect of glucagon on treating symptoms of FLD in Holstein 
dairy cows during early postpartal period. Study that uses larger number of experimental 
cows (n = 8) with homogeneous BCS might be warranted to establish stronger evidence. 
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Slow release subcutaneous glucagon implant that releases 5 mg of glucagon each 8 h co-
administered with over-the-tongue slowly dissolve glycerol paste could be tested.   
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CHAPTER 4.  GENERAL CONCLUSIONS 
General Discussion 
Our research group has proven that glucagon could prevent (Nafikov et al., 2006) and 
treat (Hippen et al., 1999; Bobe et al., 2003) fatty liver / ketosis complex in Holstein dairy 
cows. The mechanism by which glucagon improves the energy balance postpartum is 
through increasing the concentration of plasma glucose to provide the energy requirement for 
lactose milk production  and thus decreases the need for an accelerated lipolysis rates.  
Furthermore, glucagon increases the concentration of plasma insulin, which increases the 
reesterification of NEFA into TAG, resulting in decreasing plasma NEFA concentration. 
Glucagon increase plasma glucose through stimulating gluconeogenesis and glycogenolysis. 
During the peripartal period, the DMI decrease limits the availability of the gluconeogenic 
substrates that are needed to fuel gluconeogenesis such as propionate and glucogenic amino 
acids, which might imbed the action of glucagon on stimulating gluconeogenesis. 
Therefore, we hypothesized that probably the accelerated lipolysis rates peripartum is 
primarily to supply a more versatile glucogenic precursor, G-3-P, rather than only supplying 
NEFA. We based our rationale on the fact that glycerol resulting from lipolysis could be 
metabolized in the liver to G-3-P, which is converted to DHAP by the action of 
glycerolphosphate dehydrogenase. Subsequently, triose phosphate isomerase converts DHAP 
to G-3-P, which could be converted in gluconeogenesis to F-1, 6-P2 by the action of aldolase 
and then to F-6-P by F-1,6-bisphosphatase, and to  G-6-P by the action of phosphohexose 
isomerase. Finally, the glucose-6-phosphatase converts G-6-P to glucose that supplies milk 
lactose (Figure 2). 
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Alternatively, G-3-P could be used by glycolysis to directly produce energy in the form 
of ATP and pyruvate, another gluconeogenic substrate that could refuel gluconeogenesis. In 
glycolysis, G-3-P is converted to 1, 3-bisphosphoglycerate (1, 3-BPG) by the action of 
glyceraldehyde-3-phosphate dehydrogenase. Furthermore, 1, 3BPG could be converted to 
PEP and pyruvate with concomitant release of energy.  
Additionally, glycerol could be phosphorylated in liver by glycerol kinase to B-GP that is 
used to esterify excess NEFA into TAG and thus facilitates its export to extrahepatic tissues. 
Of significance, disposal of hepatic NEFA might attenuate or prevent the development of 
fatty liver. Thus, when glycerol is co-administered with glucagon, it might enhance the 
biochemical effects of glucagon on gluconeogenesis by providing the needed carbon atoms 
for glucose synthesis and facilitates removal of NEFA from the liver.  
We selected 20 multiparous Holstein cows with BCS of P 3.5 to study our hypothesis. To 
induce fatty liver, we fed them the typical dry-cow diet according to NRC (2001) 
recommendations that was supplemented with 6 kg of cracked corn (Bobe et al., 2003). By d 
7 postpartum, all our cows, except the glycerol-treated cows, developed subclinical ketosis as 
evident from the concentration of BHBA that was averaged P 1.4 mmol/L (Geishauser et al., 
1998) and peaked at 1.9 mmol/l in the control cows on d 13 postpartum as an indicator of 
severe ketosis. The glycerol treatment and the glycerol component in the glucagon plus 
glycerol treatment increased the export of TAG from liver by 4 and 5.1 mg/dL respectively 
for each decrease of 0.1 mEq/L of plasma NEFA (Figures 6A, B, and C) during the first 3 
hours on d 1 and first 1.3 hours on d 7 and 13 postpartum. Furthermore, TAG seemed to be 
secreted from liver in a pulsatile fashion. From the established correlation, it is possible that 
NEFA accumulate in liver during the postpartal period in a NEFA pool because of lack of B-
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GP needed to esterify NEFA into TAG before it could be exported to extrahepatic tissues. 
Furthermore, because NEFA contain a negatively charged hydrophobic tail, accumulated 
NEFA may disturb the hepatocytes charge balance and play an active role in the pathogenesis 
of fatty liver compared with TAG. Of interest, oleic acid accumulation inhibited cholesteryl 
esterase activity in Leydig cells (Meikle et al., 1996). Similarly, fatty liver decreases 
concentration of free cholesterol and increases cholesteryl esters (Bobe et al., 2004), which 
could be more attributed to accumulation of NEFA rather than of TAG.  
The need for the G-3-P, not NEFA, during peripartal period may better explain the 
surprising overwhelming of liver by NEFA. Because each TAG molecule is composed of one 
molecule of glycerol and 3 molecules of NEFA, for each molecule of required glycerol, liver 
has to cope with three unneeded molecules of NEFA. Apparently, the high demand for G-3-P 
by glycolysis and gluconeogenesis makes this molecule in short supply during the first few 
weeks postpartum, which necessitates increased lipolysis rates and thus hepatic NEFA 
accumulation and development of fatty liver disease. 
Therefore, the co-administration of glucagon and glycerol would make a valuable tool to 
treat fatty liver and fatty liver-related peripartal metabolic and infectious health disorders 
Recommendations for Future Research 
Our research group has conducted exhaustive research for over 20 years (De Boer et al., 
1985; Nafikov et al., 2006) to study the etiology, pathogenesis, prevention, and treatment for 
fatty liver/ketosis complex. These extensive efforts have proven that glucagon could prevent 
(Nafikov et al., 2006) and treat fatty liver (Bobe et al., 2003b) in Holstein dairy cows during 
the postpartal period and therefore, have the potential to prevent other fatty liver-related 
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peripartal metabolic and infectious health disorders. Of interest, whereas the effective 
treatment have been established for fatty liver disease, still some points in the pathogenesis 
of fatty liver disease need to be fully unraveled.  
Data from this study have indicated that probably NEFA accumulate in liver during the 
postpartal period because of short supply of B-GP needed to esterify NEFA into TAG that 
could be exported to extrahepatic tissues. Furthermore, because of the negative charge on the 
hydrophobic tail on FA, accumulation of huge amounts of NEFA might cause considerable 
charge disturbance of the hepatocytes and could play an active role in the pathogenesis of 
fatty liver. Research that studied synthesis and assembly of VLDL did not provide 
convincing evidence that directly link VLDL to the pathogenesis of fatty liver disease 
(Janovick-Guretzky et al., 2006: Piepenbrink and Overton, 2004). Similarly, carnitine 
palmitoyl transferase1 (CAT-1) activity or sensitivity to be inhibited by malonyl-CoA were 
not altered during ketosis or other fatty liver-related peripartal metabolic and infectious 
health disorders (Dann and Drackley). Furthermore, because MTP concentration, activity, or 
mRNA abundance did not correlate with liver TAG or plasma NEFA concentration, it was 
suggested that MTP does not contribute to the etiology of fatty liver disease (Bremmer et al., 
2000a: 2000b). 
Therefore, quantification of hepatic and plasma NEFA and TAG in healthy dairy cows, 
dairy cows with fatty liver, and dairy cows with fatty liver treated with 1 L of glycerol (Goff 
and Horst, 2001) starting at d 0 and continuing until d 14 postpartum might give more insight 
on the role of B-GP and G-3-P in the pathogenesis of fatty liver disease and the mechanism 
whereby liver exports TAG. Furthermore, the proposed study might give more insight on 
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how the different aspects of the dairy cow biology collaborate to alleviate the peripartal 
NEB. 
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